Статті в журналах з теми "65.011.1 (477)"
Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: 65.011.1 (477).
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "65.011.1 (477)".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
1
Pekov, Igor V., Natalia V. Zubkova, Atali A. Agakhanov, Dmitry A. Ksenofontov, Leonid A. Pautov, Evgeny G. Sidorov, Sergey N. Britvin, Marina F. Vigasina, and Dmitry Y. Pushcharovsky. "New arsenate minerals from the Arsenatnaya fumarole, Tolbachik volcano, Kamchatka, Russia. X. Edtollite, K2NaCu5Fe3+O2(AsO4)4, and alumoedtollite, K2NaCu5AlO2(AsO4)4." Mineralogical Magazine 83, no. 4 (October 2, 2018): 485–95. http://dx.doi.org/10.1180/mgm.2018.155.
Повний текст джерелаАнотація:
AbstractTwo new isostructural minerals edtollite K2NaCu5Fe3+O2(AsO4)4 and alumoedtollite K2NaCu5AlO2(AsO4)4 have been found in the Arsenatnaya fumarole, Second scoria cone of the Northern Breakthrough of the Great Tolbachik Fissure Eruption, Tolbachik volcano, Kamchatka, Russia. They are associated with sylvite, tenorite, dmisokolovite, shchurovskyite, johillerite, bradaczekite, and orthoclase. Edtollite forms prismatic crystals up to 0.02 mm × 0.1 mm; alumoedtollite forms long-prismatic crystals up to 0.01 mm × 0.1 mm. Both minerals have a semi-metallic lustre. Edtollite is brown–black to black and alumoedtollite is bronze coloured. Dcalc. = 4.26 (edtollite) and 4.28 (alumoedtollite) g cm–3. In reflected light, both minerals are grey, with distinct anisotropy. Reflectance values [edtollite/alumoedtollite: R1–R2, % (λ, nm)] are: 8.3–8.2/8.7–7.7 (470); 7.7–7.4/8.3–7.4 (546); 7.1–6.9/8.3–7.4 (589); and 6.3–6.3/7.6–7.2 (650). Chemical data are: (edtollite/alumoedtollite, wt.%, electron-microprobe): Na2O 3.13/2.58, K2O 8.12/9.09, Rb2O 0.00/0.11, CaO 0.00/0.52, CuO 36.55/38.35, ZnO 0.46/0.00, Al2O3 0.00/3.48, Fe2O3 7.34/1.79, TiO2 0.27/0.00, As2O5 43.57/43.66, total 99.44/99.58. The empirical formulae, based on 18 O apfu, for edtollite is: K1.83Na1.07Cu4.88Zn0.06Fe3+0.98Ti0.04As4.03O18; and for alumoedtollite is: K2.02Rb0.01Na0.87Ca0.10Cu5.06Al0.72Fe3+0.24As3.99O18. Both minerals are triclinic, P$\bar{1}$; unit-cell parameters (edtollite/alumoedtollite) are: a = 5.1168(6)/5.0904(11), b = 9.1241(12)/9.0778(14), c = 9.6979(14)/9.6658(2) Å, α = 110.117(13)/110.334(17), β = 102.454(12)/102.461(19), γ = 92.852(11)/92.788(15)°, V = 411.32(9)/404.88(14) Å3 and Z = 1/1. The strongest reflections in the powder X-ray diffraction pattern [d,Å(I)(hkl)] are for edtollite: 8.79(92)(001), 7.63(41)(0$\bar{1}$1), 5.22(44)(011), 3.427(100)(012), 3.148(64)(0$\bar{1}$3), 2.851(65)($\bar{1}$03) and 2.551(40)($\bar{2}$01); and for alumoedtollite: 8.78(81)(001), 7.62(67)(0$\bar{1}$1), 3.418(100)(012), 3.147(52)(0$\bar{1}$3), 2.558(58)($\bar{1}$22), 2.544(65)($\bar{2}$01) and 2.528(52)($\bar{1}\bar{3}$2). The crystal structures [single-crystal X-ray diffraction, R = 0.0773 (edtollite) and 0.0826 (alumoedtollite); 1504 and 1046 unique reflections, respectively] represent a novel structure type. It is based upon a heteropolyhedral pseudo-framework with the column formed by Cu2+-centred octahedra and square pyramids, octahedra MO6 (M = Fe3+, Al3+ or Cu2+) and AsO4 tetrahedra as the main building unit. K+ and Na+ are located in wide and narrow channels, respectively. Edtollite is named after the Russian geologist and Arctic explorer Eduard Vasilievich Toll (1858–1902), alumoedtollite is its analogue with Al prevailing among trivalent cations.
2
Ortiz, Johana, John Van Camp, Sylviana Wijaya, Silvana Donoso, and Lieven Huybregts. "Determinants of child malnutrition in rural and urban Ecuadorian highlands." Public Health Nutrition 17, no. 9 (September 30, 2013): 2122–30. http://dx.doi.org/10.1017/s1368980013002528.
Повний текст джерелаАнотація:
AbstractObjectiveTo identify and compare the sociodemographic determinants of stunting, wasting and overweight among infants of urban and rural areas in the Ecuadorian highlands.DesignCross-sectional study.SettingNabon (rural) and Cuenca (urban) cantons, Azuay Province, Ecuador.SubjectsA total of 703 children aged 0–24 months and their caregivers (227 rural and 476 urban) recruited during the period from June to September 2008.ResultsStunting prevalence was significantly higher in the rural area (37·4 %v. 17·7 %;P< 0·001) while wasting (7·1 %) and overweight (17·1 %) prevalence were more similar between areas. Determinants of stunting for the pooled sample were male gender (OR = 1·43; 95 % CI 1·06, 1·92;P= 0·02), preterm delivery (OR = 1·65; 95 % CI 1·14, 2·38;P= 0·008), child's age (OR = 1·04; 95 % CI 1·01, 1·07;P= 0·011), maternal education (OR = 0·95; 95 % CI 0·92, 0·99;P= 0·025) and facility-based delivery (OR = 0·57; 95 % CI 0·45, 0·74;P< 0·001). The latter was also a determinant of overweight (OR = 0·39; 95 % CI 0·25, 0·62;P< 0·001). Rural determinants of stunting were maternal height (OR = 0·004; 95 % CI 0·00004, 0·39;P= 0·018), diarrhoea prevalence (OR = 2·18; 95 % CI 1·13, 4·21;P= 0·02), socio-economic status (OR = 0·79; 95 % CI 0·64, 0·98;P= 0·030) and child's age (OR = 1·07; 95 % CI 1·02, 1·11;P= 0·005). Urban determinants were: maternal BMI for stunting (OR = 0·91; 95 % CI 0·84, 0·99;P= 0·027), cough prevalence (OR = 0·57; 95 % CI 0·34, 0·96;P= 0·036) and facility-based delivery (OR = 0·25; 95 % CI 0·09, 0·73;P= 0·011) for overweight, and hygiene for wasting (OR = 0·57; 95 % CI 0·36, 0·89;P= 0·013).ConclusionsInfant malnutrition was associated with different sociodemographic determinants between urban and rural areas in the Ecuadorian highlands, a finding which contributes to prioritize the determinants to be assessed in nutritional interventions.
3
Makarov, Alexander, Igor Lutkov, Anatoly Yalanetskiy, Natalia Shmigelskaia, Tamara Shalimova, Victoria Maksimovskaia, Valentina Krechetova, Dmitriy Pogorelov та Elena Ostroukhova. "О возможности производства виноматериалов для игристых вин из аборигенных сортов винограда". Magarach. Vinogradstvo i Vinodelie, № 2(108) part: 21 (19 червня 2019): 147–52. http://dx.doi.org/10.35547/im.2019.21.2.014.
Повний текст джерелаАнотація:
В статье рассмотрены физико-химические и органолептические показатели виноматериалов, выработанных из крымских и донских аборигенных сортов винограда, произрастающего в Ампелографической коллекции института «Магарач» в с. Вилино Бахчисарайского района и п. Гурзуф. Определены группы сортов, из которых получаются виноматериалы с хорошими пенистыми свойствами, оптимальным соотношением массовых концентраций винной и яблочной кислот, высокими дегустационными оценками. В частности, высокие показатели пенистых свойств (V более 800 см) определены в виноматериалах из сортов: Кокур белый 46-10-3, Кокур белый 46-10-6, Солнечная Долина 40, Солнечная Долина 71/1, Махроватчик. Средние показатели пенистых свойств (V 600-800 см) установлены в виноматериалах из сортов: Кокур белый (п. Гурзуф), Кокур белый, Кокур белый полурассеченный, Солнечнодолинский, Солнечная Долина 31а, Солнечная Долина 65, Цимлянский белый, Кефесия, Фирский ранний (с. Вилино). Массовая концентрация винной кислоты в виноматериалах варьировала в диапазоне 1,4-4,9 г/дм, яблочной кислоты - 0,1-3,2 г/дм, а лимонной - 0,1-1,2 г/дм. Более высокая массовая концентрация винной кислоты определена в виноматериалах Сых дане (4,9 г/дм), Мускат крымский (4,7 г/дм), Солнечнодолинский (4,2 г/дм), Буланый белый (4,2 г/дм), Солнечная Долина 65 (3,9 г/дм), Кокур белый (п. Гурзуф) - (3,6 г/дм), Кокур белый 46-10-3 (3,4 г/дм), Солнечная Долина 40 (3,3 г/дм), Махроватчик (3,3 г/дм), Капитан Яни кара (3,1 г/дм), а самая низкая - в виноматериале Цимлянский белый (1,4 г/дм). Показана перспективность использования для производства виноматериалов для игристых вин из винограда аборигенных сортов: Кокур белый, Кокур белый 46-10-3, Кокур белый 46-10-6, Солнечнодолинский, Солнечная Долина 40, Солнечная Долина 65, Сых дане, Сары пандас, Мускат крымский, Махроватчик, Кокур красный, Безымянный и Цимладар.The article discusses physico-chemical and organoleptic characteristics of base wines produced from Crimean and Don aboriginal grapevine cultivars grown in the Ampelographic collection of the Institute “Magarach” in Vilino village of Bakhchsarai region and in Gurzuf. Groups of cultivars which provide base wines with good sparkling properties, the optimum balance between mass concentrations of tartaric and malic acids and high tasting scores have been determined. In particular, high sparkling properties (V over 800 cm) were demonstrated by base wines from the following cultivars: ‘Kokur Belyi 46-10-3’, ‘Kokur Belyi 46-10-6’, ‘Solnechnaya Dolina 40’, ‘Solnechnaya Dolina 71/1’, ‘Mahrovatchik’. The average sparkling indexes (V 600-800 cm) were determined for base wines from the following varieties: ‘Kokur Belyi’ (v. Gurzuf), ‘Kokur Belyi’, ‘Kokur Belyi Polurassechenny’, ‘Solnechnodolinsky’, ‘Solnechnaya Dolina 31a’, ‘Solnechnaya Dolina 65’, ‘Tsimlyansky Belyi’, ‘Kefesiya’, ‘Firsky Rannyi’ (v. Vilino). Mass concentration of tartaric acid in the base wine varied between 1.4-4.9 g/dm, malic acid - 0.1-3.2 g/dm, and citric acid - 0.1-1.2 g/dm. A higher mass concentration of tartaric acid was defined for base wines from ‘Sykh Dane’ (4.9 g/dm), ‘Muscat Krymskyi’ (4.7 g/dm), ‘Solnechnodolinsky’ (4.2 g/dm), ‘Bulany Belyi’ (4.2 g/dm), ‘Solnechnaya Dolina’ 65 (3.9 g/dm), ‘Kokur Belyi’ (v. Gurzuf) - (3.6 g/dm), ‘Kokur Belyi 46-10-3’ (3.4 g/dm), ‘Solnechnaya Dolina 40’ (3.3 g/dm), ‘Mahrovatchik’ (3.3 g/dm), ‘Captain Yani Kara’ (3.1 g/dm); the lowest in ‘Tsimlyansky Belyi’ grapes (1.4 g/dm). The potential of using indigenous varieties of grapevines for the production of base wine for sparkling wines was demonstrated for the following cultivars: ‘Kokur Belyi 46-10-3’, ‘Kokur Belyi 46-10-6’, ‘Solnechnodolinsky’, ‘Solnechnaya Dolina 40’, ‘Solnechnaya Dolina 65’, ‘Sykh Dane’, ‘Sary рandas’, ‘Muscat Krymskui’, ‘Mahrovatchik’, ‘Kokur Krasnyi’, ‘Bezymyannyi’ and ‘Tsimladar’.
4
Dickinson, Michael J., Honor Cherif, Pierre Fenaux, Moshe Mittleman, Amit Verma, Maria Socorro O. Portella, Paul Burgess, and Uwe Platzbecker. "Thrombopoietin (TPO) Receptor Agonist Eltrombopag in Combination with Azacitidine (AZA) for Primary Treatment of Myelodysplastic Syndromes (MDS) Patients with Thrombocytopenia: Outcomes from the Randomized, Placebo-Controlled, Phase III Support Study." Blood 128, no. 22 (December 2, 2016): 163. http://dx.doi.org/10.1182/blood.v128.22.163.163.
Повний текст джерелаАнотація:
Abstract Introduction: Hypomethylating agents (HMA), including AZA, used to treat cytopenias in MDS patients (pts), can exacerbate thrombocytopenia. Such pts are usually treated with repeated platelet transfusions and AZA dose adjustments. Relieving thrombocytopenia may reduce platelet transfusion requirements and allow optimal AZA dosing. Eltrombopag is an oral TPO receptor agonist approved for the treatment of pts with chronic ITP, hepatitis C virus-related thrombocytopenia, and recurrent severe aplastic anemia. SUPPORT was a randomized, double-blind, placebo-controlled trial investigating the platelet supportive care effects of eltrombopag versus placebo in pts with intermediate (int)-1, int-2 or high-risk MDS receiving AZA. Methods :Adult pts with no previous exposure to HMA, baseline (BL) platelets <75x109/L and int-1, int-2 or high-risk MDS by IPSS were enrolled. Pts were randomized 1:1 to eltrombopag/AZA or placebo/AZA. Pts received eltrombopag or placebo starting at 200 mg/day (100 mg/day for East Asians), adjusted by 100 mg increments (50 mg for East Asians) to a maximum 300 mg/day (150 mg/day in East Asians) - to ensure platelet counts remained sufficient to avoid platelet transfusions and bleeding events - for as long as pts received AZA (75 mg/m2 sc once daily for 7 days, every 28 days). Treatment could continue as long as benefit was derived or until disease progression, unacceptable toxicity or death. Primary endpoint was proportion of platelet-transfusion independent pts during AZA cycles 1-4. Key secondary endpoints included overall survival (OS) and disease progression. Adverse events (AEs) were recorded from the first dose of treatment until completion of the 4-week follow-up period following discontinuation of study treatment. Following a planned interim assessment, an independent data monitoring committee recommended stopping the study prematurely because outcomes crossed the pre-defined futility threshold and for safety reasons. Here we report the primary analyses from all randomized pts at the time of trial termination. Results:356 pts (median age 70 [range 24-89] years) received eltrombopag (n=179; n=64 int-1, n=77 int-2, n=38 high-risk) or placebo (n=177; n=61 int-1, n=83 int-2, n=33 high-risk). 29 (16%) eltrombopag and 37 (21%) placebo pts were platelet-transfusion dependent at BL. Median time on AZA plus eltrombopag or placebo was 83 (range 1-477) vs 149 (8-503) days. Most common reasons (≥10%) for treatment discontinuation on eltrombopag or placebo, respectively, were study termination (32 vs 44%), AZA discontinuation (30 vs 26%) and AEs (22 vs 14%). Median eltrombopag or placebo doses were 113 (range 60-148) vs 122 (81-147) mg/day in East Asians and 200 (65-293) vs 262 (107-316) mg/day in non-East Asians. At an interim analysis (n=147 evaluable pts), 13/79 (16%) eltrombopag and 27/68 (40%) placebo pts were platelet-transfusion independent [OR: 0.25, 95% CI: 0.11, 0.61; one-sided P=1.000], crossing the pre-defined futility boundary. At premature (primary and final analysis) study termination (n=356), 28/179 (16%) eltrombopag and 55/177 (31%) placebo pts were platelet-transfusion independent during the first 4 cycles of AZA (OR: 0.37, 95% CI: 0.21, 0.65; one-sided P=1.000). At study closure, 57 (32%) and 51 (29%) pts had died in the eltrombopag and placebo arms, respectively, with 33 (19%) and 29 (16%) deaths within 30 days after end of treatment; the main causes of death (≥10%) were disease under study (16 vs 12%) and sepsis (10 vs 7%). Disease progression (investigator-assessed) had occurred in 38 (21%) and 30 (17%) pts in the eltrombopag and placebo groups, respectively, at the time of study discontinuation. The most common AEs for eltrombopag are summarized (Table). Conclusions: In contrast to published reports on eltrombopag monotherapy inducing platelet transfusion independence in MDS pts, eltrombopag given concomitantly with AZA was inferior to placebo/AZA. There was no difference in overall deaths between the two groups. A complete assessment of disease progression, including AML progression at the time of study termination, is in progress. Pharmacodynamic antagonism between AZA and eltrombopag is proposed as one potential explanation for these results; further analyses and preclinical studies are ongoing to determine a possible mechanism of drug-drug interaction and the impact of drug sequencing on this potential association. Disclosures Dickinson: GlaxoSmithKline: Consultancy, Research Funding. Fenaux:Celgene, Janssen, Novartis, Astex, Teva: Research Funding; Celegene, Novartis, Teva: Honoraria. Mittleman:Celgene, Novartis, Janssen: Speakers Bureau; Novartis, Pfizer, Janssen, Roche: Consultancy. Portella:Novartis: Employment. Burgess:Novartis: Employment. Platzbecker:Celgene Corporation: Honoraria, Research Funding; TEVA Pharmaceutical Industries: Honoraria, Research Funding; Amgen: Honoraria, Research Funding; Janssen-Cilag: Honoraria, Research Funding; Novartis: Honoraria, Research Funding.
5
Arora, Sukeshi Patel, Nishant Gandhi, Phillip Walker, Anthony Frank Shields, Andreas Seeber, Gilberto Lopes, Nelson Yee, et al. "Molecular profile of hepatocellular carcinoma (HCC) in older versus younger adults: Does age matter?" Journal of Clinical Oncology 40, no. 4_suppl (February 1, 2022): 477. http://dx.doi.org/10.1200/jco.2022.40.4_suppl.477.
Повний текст джерелаАнотація:
477 Background: HCC is increasingly prevalent in older adults with rising incidence and an aging population worldwide. Retrospective studies show older patients with HCC may have an increased survival compared to younger patients. However, data is lacking regarding the genomic and biologic differences, that if identified, would potentially change how we treat this disease in younger vs. older patients. Hence, there is a need to better characterize the molecular landscape of the disease in an age-specific manner. We analyzed the association of age with genomic alterations and therapeutic response to sorafenib in a cohort of advanced HCC that had undergone comprehensive molecular profiling. Methods: 487 HCC samples (excluding variants) were analyzed using Next Generation Sequencing (592 gene panel, NextSeq), Whole Exome and Whole Transcriptome Sequencing (NovaSeq), and IHC at Caris Life Sciences (Phoenix, AZ). PD-L1 positivity was determined by IHC (SP-142 clone, cutoff ≥1, 1%). Tumor mutational burden (TMB) was a measure of total somatic mutations per Mb. Immune cell populations were determined by Microenvironment Cell Population (MCP) counter analysis of RNA expression data. Overall survival (OS) calculated from tissue collection to last contact and time on treatment (TOT) with sorafenib were extracted from insurance claims and calculated using Kaplan-Meier curves. Statistical analysis was done using Chi-square, Fisher Exact and Wilcoxon rank sum tests, with p values adjusted for multiple comparisons and q<0.05. Results: Differences in the molecular landscape of HCC stratified by patient age were assayed using a ternary classification based on 1 standard deviation from the mean age (mean age=65; <53: A1 (n=51), 53-77: A2 (n=361), >77: A3 (n=75)). With age, mutational frequencies in CTNNB1 (A1=13.04%, A2=33.43%, A3=38.24%) and TERT (A1=25%, A2=68.84%, A3=76.92%) increased, while ATM (A1=6.52%, A2=0.93%, A3=1.49%) decreased (p<0.05, q>0.05). There were fold increases in median TMB (A2/A1=1.33, A3/A1=1.33, p<0.01), LAG3 (A2/A1=1.75, A3/A1=1.93 p<0.01), CTLA4 (A2/A1=2.05, A3/A1=2.15, p<0.05) expression; median cell fractions of CD8+ T cells (A2/A1=1.37, A3/A1=1.50, p<0.05) & B cells (A3/A1=3.01 p<0.05) increased while cancer associated fibroblasts (A1/A2=0.62, A1/A3=0.69, p<0.01) decreased with age. PD-L1 was not statistically significant. While there was no change in OS, reduced TOT with sorafenib was observed in patients aged>65 (p=0.013). Conclusions: Increased alterations in oncogenic drivers and estimates of CD8+ T cells and B cells were observed in the elderly population with HCC. The enhanced presence of co-inhibitory molecules suggests potential immune evasion. While we observed reduced TOT with sorafenib, additional studies are needed to elucidate the impact of molecular alterations on outcomes with sorafenib and newer therapies (i.e. immunotherapy) in older adults.
6
Christie, Dudley B., Timothy E. Nowack, Cory J. Nonnemacher, Anne Montgomery, and Dennis W. Ashley. "Surgical Stabilization of Rib Fractures Improves Outcomes in the Geriatric Patient Population." American Surgeon 88, no. 4 (January 3, 2022): 658–62. http://dx.doi.org/10.1177/00031348211060432.
Повний текст джерелаАнотація:
Introduction Rib fractures in the ≥65-year-old population have been shown to strongly influence mortality and pneumonia rates. There is a growing body of evidence demonstrating improvements in the geriatric patient’s survival statistics and respiratory performances after surgical stabilization of rib fractures (SSRF). We have observed a strong survival and complication avoidance trend in geriatric patients who undergo SSRF. The purpose of our study was to evaluate the outcomes of geriatric patients with rib fractures treated with SSRF compared to those who only receive conservative therapies. Methods We performed a retrospective review of our trauma registry analyzing outcomes of patients ≥65 years with rib fractures. Patients admitted from 2015 to 2019 receiving SSRF (RP group) were compared to a nonoperative controls (NO group) admitted during the same time. Bilateral fractures were excluded. Independent variables analyzed = ISS, mortalities, hospital days, ICU days, pleural space complications, and readmissions. Follow-up was 60 days after discharge. Group comparison was performed using Kolmogorov-Smirnov, Shapiro-Wilk, and Mann-Whitney U tests. Results 257 patients were analyzed: 172 in the NO group with mean age of 75 (65-10) and 85 in the RP group with mean age of 74 (65-96). Mean ISS = 13 (1-38) for the NO group and 20 (9-59) for the RP group ( P < .001). Mean hospital days = 8 (1-39) and 15 (3-49) in NO and RP groups, respectively. Mean ICU days = 10 (1-32) and 8 (1-11) in NO and RP groups, respectively. Deaths, pneumonia, readmissions, and pleural effusions in the NO group were statistically significant ( P < .01). Analysis of complications revealed 4 RP patients (4.7%) with respiratory complications out to 60 days and 65 NO patients (37.8%) ( P < .001). Conclusions Surgical stabilization of rib fractures appears to be associated with a survival advantage and an avoidance of respiratory-related complications in the ≥65-year-old patient population.
7
Widgren, Ylva, Per Fransson, and Anna Efverman. "Acupuncture in Patients Undergoing Cancer Therapy: Their Interest and Belief in Acupuncture is High, But Few are Using It." Integrative Cancer Therapies 21 (January 2022): 153473542210772. http://dx.doi.org/10.1177/15347354221077277.
Повний текст джерелаАнотація:
Objectives: Since pre-existing expectations, that is, beliefs, in a treatment may modify outcomes, and acupuncture studies often fail to measure expectations, we wanted to investigate the use of acupuncture, interest, and belief in acupuncture effects among patients undergoing cancer therapy. Method: A cross-sectional design, where the participants answered a study-specific questionnaire with questions regarding their use of, interest and belief in acupuncture treatment. Results: A total of 457 patients with cancer (48% men, mean age 65 years) answered the questionnaire. Acupuncture was used by 4 (1%) patients during their cancer therapy, and 368 (83%) expressed an interest in receiving acupuncture. Of the 457 patients, 289 (63%) believed acupuncture to be effective for at least 1 of 17 requested symptoms, most commonly pain (56% of the patients) and muscle tension (40%). They believed acupuncture to be effective for a mean value 3 of the 17 requested symptoms. Women ( P < .001), and patients 41 to 65 years ( P < .001), expressed a stronger belief in acupuncture effects than others. Conclusions: Men and older patients expressed weaker beliefs in acupuncture effects than other patients, indicating the importance of collecting expectancy data in future randomized sham-controlled acupuncture studies to be able to treat expectancy as an effect-modifier. The high interest and beliefs in acupuncture effects found also indicate that acupuncture should be available for patients with cancer, for side effects where acupuncture has shown to be effective. In a clinical setting, older men might need more encouragement regarding positive expected outcomes of the acupuncture treatment than younger women.
8
Rennerfelt, Kajsa, Qiuxia Zhang, Jón Karlsson, and Jorma Styf. "Patient pain drawing is a valuable instrument in assessing the causes of exercise-induced leg pain." BMJ Open Sport & Exercise Medicine 4, no. 1 (January 2018): e000262. http://dx.doi.org/10.1136/bmjsem-2017-000262.
Повний текст джерелаАнотація:
AimWe validated patientpain drawing (PPD) in establishing the diagnosis of chronic anterior compartment syndrome (CACS) in patients with exercise-induced leg pain.MethodsThe study comprised 477 consecutive patients, all suspected of having CACS. The diagnosis was based on the patient’s history, a thorough clinical examination and measurements of intramuscular pressure (IMP) following an exercise test. Patients completed a PPD before their hospital visit. Two independent orthopaedic surgeons diagnosed the causes of leg pain based only on the PPD at least 1 year after admission. Based on the results of diagnostic tests, the patients were divided into three groups: CACS (n=79), CACS with comorbidity (n=89) and non-CACS (n=306).ResultsThe sensitivity of the PPD to identify CACS correctly was 67% (observer 1) and 75% (observer 2). The specificity was 65% and 54%, respectively. The interobserver agreement (n=477) was 80%, and the kappa value was 0.55. The interobserver agreement was 77%, and the kappa value was 0.48 among 168 CACS patients with or without comorbidity. The interobserver agreement was 85%, and the kappa value was 0.56 in 79 CACS, and CACS was correctly diagnosed in 79% (observer 1) and 82% (observer 2). The test–retest showed the same results for the two observers, with an intraobserver agreement of 84%, while the test–retest reliability coefficient was 0.7. Comorbidity was found in 53% of CACS patients.ConclusionPPD might be a valuable instrument in diagnosing the causes of exercise-induced leg pain. It is useful in identifying CACS with and without comorbidity.
9
Rubio, I., A. Martínez-Bueno, G. López-Vivanco, N. Fuente, R. Barceló, A. Gil-Negrete, S. Carrera, G. López-Argumedo, R. Fernández, and A. Muñoz. "Elderly patients with advanced non-small cell lung cancer (nsclc). Results of chemotherapy and comparison with younger patients." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 18505. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.18505.
Повний текст джерелаАнотація:
18505 Background: Lung cancer is increasingly diagnosed in elderly patients and is the first cause of cancer death. Treatment of this subset represents a challenge to medical oncologists. Methods: We retrospectively reviewed clinical characteristics, co-morbidity (Charlson Index), toxicity and results of all patients ≥ 65 years (y) old, diagnosed of advanced NSCLC. We compared these results with younger patients’. Results: From January-95 to June-02, we treated 477 patients (pt), 176 ≥ 65 years, 301 < 65 y. Treatment: 177 pt, MIC (mitomycine + ifosfamide + cisplatin), 60 ≥ 65 y and 117 < 65 y; 156, CG (Cisplatin + Gemcitabine), 52 > 65 y and 104 < 65 y; 144, CP (Cisplatin + Paclitaxel), 64 ≥ 65 y and 120 < 65 y. Characteristics: median age 60 (31–78); 428 male, 49 female; ECOG 0/1/2/3: 83/312/71/5, Stage IIIA, IIIB and IV: 72/199/206, Histology: squamous carcinoma 215, adenocarcinoma 190, large cell 19, bronchioloalveolar 7, undifferentiated 45 pt. No significant differences between the two groups. Overall response rate: 39% (CR, 32.9%, PR, 6.1%), Stable disease 26.4% and Progressive disease, 26.4%. Patients ≥ 65 y: CR 5.7%, PR 45.5%, SD 23.3% and PD 18.2%. Patients < 65 y: CR 6.3% PR 25.6%, SD 28.2% and PD 31.2%. Predictive factors for response: ECOG and stage. Response rate was superior in patients ≥ 65 y and in patients ≥ 70 y. Overall survival: 38.29 weeks (w): < 65 y, 38.57 w; 65–70 y, 37.71 w and ≥ 70 y, 37 w. Multivariate analysis: ECOG, stage and sex were prognostic factors; age, histology, Charlson index and schedule treatment were not significant. Grade 3/4 episodes of toxicity: ≥ 65 y, 184/17, and < 65 y, 232/8. Treatment delays: ≥ 65 y, 115 and < 65 y, 100. Hospitalization due to toxicity: >≥ 65 y, 34 and < 65 y, 23. Treatment was stopped in 13 pt >≥ 65 y and in 7 pt < 65 y. Conclusions: Age is not a predictive factor for response to chemotherapy, neither a prognostic factor for survival. Charlson index does not seem to be useful for these patients. Although toxicity is superior, cisplatin-based schedules are safe and active. No significant financial relationships to disclose.
10
Nikitin, Kirill D., Sergei B. Fitilev, Tatiana V. Chernovskaya, Elena G. Rudenko, Alexander V. Vozzhaev, Yulia Y. Titarova, Vadim A. Yakushev, and Roman A. Ivanov. "Pharmacokinetics, pharmacodynamics, and tolerability of BCD-017, a novel pegylated filgrastim: Results of open-label controlled phase I study with dose escalation in healthy volunteers." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 9060. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.9060.
Повний текст джерелаАнотація:
9060 Background: Pegfilgrastim (conjugate of filgrastim and 20 kDa PEG) is approved for treatment of chemotherapy-associated neutropenia. BCD-017 is a covalent conjugate of filgrastim with 30 kDa PEG. Increased molecular weight of PEG molecule may provide additional benefits compared to pegfilgrastim. We have conducted this open-label phase I study to assess the PK, PD and tolerability of BCD-017. Methods: 24 healthy male volunteers signed the informed consent and were sequentially assigned to receive 1, 3 or 9 mg of BCD-017 or 5 mcg/kg/day of filgrastim for 7 days, 6 volunteers per group. Outcome measures included absolute neutrophil count (ANC) and СD34+ cell count, PK parameters and adverse events (AEs). Results: BCD-017 induced a fast and significant increase of ANC. Median maximum ANC (ANCmax) for BCD-017 1, 3, 9 mg and filgrastim was 18.68 (10.62-21.02), 25.92 (15.43-28.07), 32.22 (18.22-45.79), and 28.21 (21-31.95) ×103 cells/mm3, respectively; median time to ANCmax was 24 (12-24); 48 (24-72); 72 (48-72); and 132,5 (12-169) h, respectively; median increase in СD34+ cells number 96 h post dose was 4.7 (1.2-6.5), 6.5 (1.7-12.3), 40.9 (24.5-102), and 17.8 (3.3-35.2) times, respectively. Filgrastim serum concentration was analyzed using ELISA. Median Cmax for BCD-017 3 and 9 mg and filgrastim was 45 (31-65), 446 (191-649), and 40 (20-54) ng/mL, respectively; median Tmax was 48 (24-72), 36 (24-48), and 8 (6-8) h respectively; median T1/2 was 65 (51-70), 46 (41-57), and 6.7 (6.2-7.6) h, respectively. BCD-017 was well tolerated. No dose-limiting AEs were observed. AEs included headache, back pain, myalgia, arthralgia, thrombocytopenia, hyperuricemia, alkaline phosphatase/LDH increased. All AEs were of grade 1-2. Compared to filgrastim, the best tolerability was observed in 3 mg group. Conclusions: BCD-017 is shown to be a potent stimulator of granulopoiesis. BCD-017 3 mg did not differ from filgrastim in terms of ANC increase and its safety was shown in healthy volunteers. Further phase II study of BCD-017 for treatment and prophylaxis of neutropenia in patients receiving cytotoxic chemotherapy is necessary.
11
Bonnet, R., C. De Champs, D. Sirot, C. Chanal, R. Labia, and J. Sirot. "Diversity of TEM Mutants in Proteus mirabilis." Antimicrobial Agents and Chemotherapy 43, no. 11 (November 1, 1999): 2671–77. http://dx.doi.org/10.1128/aac.43.11.2671.
Повний текст джерелаАнотація:
ABSTRACT In a survey of resistance to amoxicillin among clinical isolates ofProteus mirabilis, 10 TEM-type β-lactamases were characterized: (i) the well-known penicillinases TEM-1 and TEM-2, the extended-spectrum β-lactamases (ESBLs) TEM-3 and TEM-24, and the inhibitor-resistant TEM (IRT) TEM-44 and (ii) five novel enzymes, a penicillinase TEM-57 similar to TEM-1, an ESBL TEM-66 similar to TEM-3, and three IRTs, TEM-65, TEM-73, and TEM-74. The penicillinase TEM-57 and the ESBL TEM-66 differed from TEM-1 and TEM-3, respectively, by the amino acid substitution Gly-92→Asp (nucleotide mutation G-477→A). This substitution could have accounted for the decrease in pIs (5.2 for TEM-57 and 6.0 for TEM-66) but did not necessarily affect the intrinsic activities of these enzymes. The IRT TEM-65 was an IRT-1-like IRT (Cys-244) related to TEM-2 (Lys-39). The two other IRTs, TEM-73 and TEM-74, were related to IRT-1 (Cys-244) and IRT-2 (Ser-244), respectively, and harbored the amino acid substitutions Leu-21→Phe and Thr-265→Met. In this study, the ESBLs TEM-66, TEM-24, and TEM-3 were encoded by large (170- to 180-kb) conjugative plasmids that exhibited similar patterns after digestion and hybridization with the TEM and AAC(6′)I probes. The three IRTs TEM-65, TEM-73, and TEM-74 were encoded by plasmids that ranged in size from 42 to 70 kb but for which no transfer was obtained. The characterization of five new plasmid-mediated TEM-type β-lactamases and the first report of TEM-24 in P. mirabilis are evidence of the wide diversity of β-lactamases produced in this species and of its possible role as a β-lactamase-encoding plasmid reservoir.
12
Hautala, Arto J., Arthur S. Leon, James S. Skinner, D. C. Rao, Claude Bouchard та Tuomo Rankinen. "Peroxisome proliferator-activated receptor-δ polymorphisms are associated with physical performance and plasma lipids: the HERITAGE Family Study". American Journal of Physiology-Heart and Circulatory Physiology 292, № 5 (травень 2007): H2498—H2505. http://dx.doi.org/10.1152/ajpheart.01092.2006.
Повний текст джерелаАнотація:
We tested the hypothesis that peroxisome proliferator-activated receptor-δ (PPARδ) gene polymorphisms are associated with cardiorespiratory fitness and plasma lipid responses to endurance training. Associations between the PPARδ exon 4 +15 C/T and exon 7 +65 A/G polymorphisms and maximal exercise capacity and plasma lipid responses to 20 wk of endurance training were investigated in healthy white ( n = 477) and black ( n = 264) subjects. In black subjects, the exon 4 +15 C/C homozygotes showed a smaller training-induced increase in maximal oxygen consumption ( P = 0.028) than the C/T and T/T genotypes. Similarly, a lower training response in maximal power output was observed in the exon 4 +15 C/C homozygotes ( P = 0.005) compared with the heterozygotes and the T/T homozygotes in black subjects, and a similar trend was evident in white subjects ( P = 0.087). In white subjects, baseline apolipoprotein A-1 (Apo A-1)levels were higher in the exon 4 +15 C/C ( P = 0.011) and exon 7 +65 G/G ( P = 0.05) genotypes compared with those in the other genotypes. In white subjects, exon 4 +15 C/C ( P = 0.0025) and exon 7 +65 G/G ( P = 0.011) genotypes showed significantly greater increases in plasma high-density lipoprotein-cholesterol (HDL-C) levels with endurance training than in the other genotypes, whereas in black subjects the exon 4 +15 CC homozygotes tended to increase ( P = 0.057) their Apo A-1 levels more than the T allele carriers. DNA sequence variation in the PPARδ locus is a potential modifier of changes in cardiorespiratory fitness and plasma HDL-C in healthy individuals in response to regular exercise.
13
Cortes, Jorge E., Qian Jiang, Jianxiang Wang, Jianyu Weng, Huanling Zhu, Liu Xiaoli, Andreas Hochhaus, et al. "Dasatinib Versus Imatinib in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Not Achieved an Optimal Response to 3 Months of Imatinib Therapy: Dascern." Blood 132, Supplement 1 (November 29, 2018): 788. http://dx.doi.org/10.1182/blood-2018-99-111978.
Повний текст джерелаАнотація:
Abstract Introduction: Treatment with dasatinib, a second-generation tyrosine kinase inhibitor (TKI), has resulted in high rates of cytogenetic and molecular responses for pts with CML-CP, both as initial therapy and after failure of other therapies. A reduction in BCR-ABL1 transcript levels to ≤ 10% on the International Scale (IS) at 3 mo is associated with an improved probability of deep molecular responses and superior progression-free and overall survival (PFS and OS). In DASISION, considerably more pts treated with dasatinib achieved BCR-ABL1 ≤ 10% IS compared to imatinib. BCR-ABL1 ≤ 10% IS at 3 mo is considered an optimal response by international guidelines; however, approximately one-third of pts with CML-CP on first-line (1L) imatinib will not achieve this threshold. Clinical studies exploring the potential benefit of early switching to dasatinib in pts with less than optimal responses on initial imatinib treatment have not been reported. Methods: DASCERN (NCT01593254) is a randomized, open-label, international phase 2b trial in adult pts with CML-CP who had achieved complete hematologic response (CHR) but who had BCR-ABL1 > 10% IS at 3 mo after initial treatment with 400 mg imatinib once daily (QD). Imatinib must have been started within 6 mo of the initial CML-CP diagnosis. Pts were randomized 2:1 to receive 100 mg dasatinib QD or continue imatinib at ≥ 400 mg daily with the option for dose escalation. Pts initially randomized in the imatinib cohort who met European LeukemiaNet 2013 failure criteria after randomization and without dasatinib-resistant mutations were crossed over to the dasatinib arm. The primary endpoint in DASCERN is the rate of MMR (BCR-ABL1 < 0.1% IS) at 12 mo after day 1 initiation of 1L imatinib (9 mo after randomization). Secondary endpoints include time to MMR, OS, and PFS (progression was defined as transformation to accelerated/blast phase or death). Tertiary endpoints include safety and tolerability profile of both treatment arms and cytogenetic response over time. Results: All 260 randomized pts (dasatinib: n = 174; imatinib: n = 86) had a minimum follow-up of ≥ 12 mo from the last pts 1st visit (Sokal scores: 28% low, 30% intermediate, 24% high, 18% unknown; median age 37 y [range 18-82, 95% were < 65 y]; 78% male; 73% Asian). All pts had e13a2 or e14a2 transcript types. At the time of analysis, 84% of pts were continuing in the study. Median daily dose was 100 mg QD (range 26-142) for dasatinib and 400 mg QD (range 129-825) for imatinib. Median treatment duration was 111 wk (774 d) in the dasatinib arm and 68 wk (477 d) in the imatinib arm; 42 (49%) imatinib-randomized pts crossed over to dasatinib. Rate of MMR at 12 mo in the intent-to-treat population was 29% (95% confidence interval [CI] 22, 36) for dasatinib and 13% (95% CI 7, 22) for imatinib (P = 0.005); median time to MMR was 14 mo (range 12-18) for dasatinib vs 20 mo (range 14-26) for imatinib (P = 0.053). No differences in the rate of progression or OS were observed between treatment arms. No new safety signals were observed for either treatment arm and the early switch to dasatinib did not increase the toxicity rate. Treatment-emergent pleural effusion (PE; any grade) occurred in 11 (6%) pts randomized to dasatinib and 3 (7%) imatinib-randomized pts who crossed over to dasatinib; treatment-emergent PE grade 3/4 occurred in 1 (1%) pt randomized to dasatinib and 2 (5%) pts randomized to imatinib who crossed over to dasatinib. Hematologic toxicity was similar between treatment arms: neutropenia grade 3/4 occurred in 18 (11%) pts randomized to dasatinib and 12 (29%) pts randomized to imatinib who crossed over to dasatinib; thrombocytopenia grade 3/4 occurred in 18 (11%) pts randomized to dasatinib and in 7 (17%) pts randomized to imatinib who crossed over to dasatinib. Two dasatinib-treated pts discontinued due to hematologic toxicity (1 neutropenia, 1 thrombocytopenia). Conclusions: Early results from DASCERN show that pts with suboptimal responses to imatinib at 3 mo who switched to dasatinib had a significantly increased rate of MMR at 12 mo compared to pts who remained on imatinib. Longer follow-up is required to assess the impact of early switching on PFS and OS, and achievement of deep molecular responses. Disclosures Cortes: Astellas Pharma: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Daiichi Sankyo: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Arog: Research Funding. Hochhaus:Bristol-Myers Squibb: Research Funding; Pfizer: Research Funding; Novartis: Research Funding; Incyte: Research Funding; Takeda: Research Funding. Kim:BMS: Research Funding; Ilyang: Research Funding; Pfizer: Research Funding; Novartis: Research Funding. Savona:Boehringer Ingelheim: Consultancy; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Incyte: Membership on an entity's Board of Directors or advisory committees, Research Funding. Martin Regueira:Bristol-Myers Squibb: Employment, Equity Ownership. Sy:Bristol-Myers Squibb: Employment. Gurnani:Bristol-Myers Squibb: Employment.
14
Luque, Y., E. Kerhervé, N. Deltimple, and D. Belot. "Design challenges of a fully integrated 65 nm CMOS half cascode SFDS PA." Analog Integrated Circuits and Signal Processing 70, no. 2 (August 28, 2011): 181–87. http://dx.doi.org/10.1007/s10470-011-9735-1.
Повний текст джерела
15
Chi, Kim N., Sebastien J. Hotte, Susan Ellard, Joel Roger Gingerich, Anthony Michael Joshua, Evan Y. Yu, and Martin Edwin Gleave. "A randomized phase II study of OGX-427 plus prednisone (P) versus P alone in patients (pts) with metastatic castration resistant prostate cancer (CRPC)." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 4514. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.4514.
Повний текст джерелаАнотація:
4514 Background: Heat Shock Protein 27 (Hsp27) is a multi-functional chaperone protein that regulates cell signaling and survival pathways implicated in cancer progression. In prostate cancer models, Hsp27 complexes with androgen receptor (AR) and enhances transactivation of AR-regulated genes. OGX-427 is a 2nd generation antisense oligonucleotide that inhibits Hsp27 expression with in vitro and in vivo efficacy and was well tolerated with single agent activity in phase I studies. Methods: Chemotherapy-naïve pts with no/minimal symptoms were randomized to receive OGX-427 600 mg IV x 3 loading doses then 1000 mg IV weekly with P 5 mg PO BID or P only. Primary endpoint was the proportion of pts progression free (PPF) at 12 weeks (PCWG2 criteria). A 2-stage MinMax design (H0 = 5%, HA >20%, α=0.1, β=0.1) with 32 pts/arm provides 70% power to detect the difference at 0.10 1-sided significance. Secondary endpoints include PSA decline, measurable disease response, and circulating tumour cell (CTC) enumeration. Results: 38 pts have been enrolled; 1st stage of accrual completed with 2nd stage accruing. In the 1st 32 pts randomized (17 to OGX-427+P, 15 to P), baseline median age was 71 years (53-89), ECOG PS 0 or 1 in 66% and 34% of pts, median PSA 66 (6-606), metastases in bone/lymph nodes/liver or lung was 75/56/9%, 31% had prior P treatment, and 93% had ≥5 CTC/7.5 ml. Predominantly grade 1/2 infusion reactions (chills, diarrhea, flushing, nausea, vomiting) occurred in 47% of pts receiving OGX-427+P. One pt on OGX-427+P developed hemolytic uremic syndrome. A PSA decline of ≥50% occurred in 41% of pts on OGX-427+P, and 20% of pts treated with P. A measurable disease partial response was seen in 3/8 (38%) evaluable pts on OGX-427+P and 0/9 pts on P. CTC conversion from ≥5 to <5/7.5 ml occurred in 50% of pts on OGX-427+P and 31% treated with P. Thus far, in 26 evaluable pts the PPF at 12 weeks was 71% (95% CI: 42-92) in OGX-427+P treated pts and 33% (95% CI: 10-65) in pts on P. Conclusions: These data provide clinical evidence for the role of Hsp27 as a therapeutic target in prostate cancer and support continued evaluation of OGX-427 for pts with CRPC. Funded by a grant from the Terry Fox Research Institute.
16
Lidman, F., C. M. Mörth, and H. Laudon. "Landscape control of uranium and thorium in boreal streams – spatiotemporal variability and the role of wetlands." Biogeosciences 9, no. 11 (November 23, 2012): 4773–85. http://dx.doi.org/10.5194/bg-9-4773-2012.
Повний текст джерелаАнотація:
Abstract. The concentrations of uranium and thorium in ten partly nested streams in the boreal forest region were monitored over a two-year period. The investigated catchments ranged from small headwaters (0.1 km2) up to a fourth-order stream (67 km2). Considerable spatiotemporal variations were observed, with little or no correlation between streams. The fluxes of both uranium and thorium varied substantially between the subcatchments, ranging from 1.7 to 30 g km−2 a−1 for uranium and from 3.2 to 24 g km−2 a−1 for thorium. Airborne gamma spectrometry was used to measure the concentrations of uranium and thorium in surface soils throughout the catchment, suggesting that the concentrations of uranium and thorium in mineral soils are similar throughout the catchment. The fluxes of uranium and thorium were compared to a wide range of parameters characterising the investigated catchments and the chemistry of the stream water, e.g. soil concentrations of these elements, pH, TOC (total organic carbon), Al, Si and hydrogen carbonate, but it was concluded that the spatial variabilities in the fluxes of both uranium and thorium mainly were controlled by wetlands. The results indicate that there is a predictable and systematic accumulation of both uranium and thorium in boreal wetlands that is large enough to control the transport of these elements. On the landscape scale approximately 65–80% of uranium and 55–65% of thorium entering a wetland were estimated to be retained in the peat. Overall, accumulation in mires and other types of wetlands was estimated to decrease the fluxes of uranium and thorium from the boreal forest landscape by 30–40%, indicating that wetlands play an important role for the biogeochemical cycling of uranium and thorium in the boreal forest landscape. The atmospheric deposition of uranium and thorium was also quantified, and its contribution to boreal streams was found to be low compared to weathering.
17
Álvarez-Reguera, C., J. J. Gaitán-Valdizán, R. Fernández-Ramón, R. Demetrio-Pablo, J. L. Martín-Varillas, L. Sanchez-Bilbao, D. Martínez-López, I. González-Mazón, M. Á. González-Gay, and R. Blanco. "POS0740 EPIDEMIOLOGY AND CLINICAL FEATURES OF OCULAR SARCOIDOSIS. STUDY OF 65 PATIENTS OF A SERIES OF 384 PATIENTS FROM A SINGLE UNIVERSITY HOSPITAL." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 621.2–622. http://dx.doi.org/10.1136/annrheumdis-2021-eular.1930.
Повний текст джерелаАнотація:
Background:Ocular involvement in sarcoidosis can be present in up to 80% of patients. If not treated, it can lead to significant visually complications (1-5).Objectives:Our aim was to assess the main a) epidemiology and b) clinical features of ocular sarcoidosis in a wide and unselected series from a single university hospital.Methods:Study of a large cohort (n=384) of all consecutive patients diagnosed with sarcoidosis from January 1, 1999 to December 31, 2019. Finally, 344 patients were included according to the ATS/ERS/WASOG criteria (Eur Respir J. 1999;14:735-7).Results:65 (33 men/32 women) of 344 (18.9%) patients had ocular involvement. Mean age at diagnosis was 45.6±15.9 years. The most frequent extraocular clinical clusters were respiratory (80%), osteoarticular (30.8%) and cutaneous (29.2%) (figure 1). Ocular manifestations and complications are shown in table 1. Uveitis (83.1%), orbital lesions (7.7%) and retinal vasculitis (6.2%) were the most common ocular lesions. Median Best Corrected Visual Acuity (BCVA) at diagnosis and after one year of follow-up was 0.6 [0.3-0.8] and 0.9 [0.30-1], respectively. Retinal vasculitis was associated to the worst BCVA outcome, and panuveitis to more frequent and severe complications.Conclusion:Ocular manifestations, especially uveitis, are frequent in sarcoidosis. A more aggressive and early treatment may be indicated in panuveitis and retinal vasculitis.References:[1]Riancho-Zarrabeitia L, et al. Semin Arthritis Rheum 2015;45:361-8.[2]Riancho-Zarrabeitia L et al. Clin Exp Rheumatol 2014; 32:275-84.[3]Vegas-Revenga N, et al. Am J Ophthalmol 2019; 200:85-94.[4]Calvo-Río V, et al. Clin Exp Rheumatol 2014; 32 (4 Suppl 84): S54-7. Epub 2014 Jul 8.[5]Cordero-Coma et al. Mediators Inflamm. 2014; 2014:717598.Figure 1.Clinical clusters of associations in ocular sarcoidosis.Table 1.Ocular manifestations and associated complications after 1 year of follow-up of 65 patients with ocular sarcoidosis.Type of ocular affectationN (%)Median BCVA at onset[IQR]Median BCVA after 1 year of follow-up[IQR]CataractN (%)OPN (%)OHTN (%)CMEN (%)ERMN (%)Uveitis, pattern54 (83.1)0.6 [0.3-0.8]0.9 [0.6-1]18 (27.7)11 (16.9)7 (10.8)7 (10.8)8 (12.3)Anterior31 (47.7)0.7 [0.3-0.8]0.8 [0.5-1]13 (41.9)2 (6.5)2 (6.5)2 (6.5)2 (6.5)Panuveitis16 (24.6)0.4 [0.2-0.7]0.9 [0.5-1]5 (31.3)7 (43.8)4 (25)5 (31.3)5 (31.3)Posterior5 (5.2)0.5 [0.1-0.9]0.9 [0.9-1]02 (40)1 (20)00Intermediate2 (3.1)0.50.700001Orbitary lesions5 (7.7)0.5 [0.1-0.6]1 [0.1-1]1 (20)01 (20)00Retinal vasculitis4 (6.2)0.6 [0.5-0.8]1 [0.6-1]00001 (25)Dry eye4 (6.2)10.900000Scleritis10.61.000000Abbreviations: BCVA: Best corrected visual acuity; CME: Cystoid macular edema ERM: Epiretinal membrane; OP: Optic Papillitis; OHT: Ocular hypertension.Disclosure of Interests:Carmen Álvarez-Reguera: None declared, Jorge Javier Gaitán-Valdizán: None declared, Raúl Fernández-Ramón: None declared, Rosalía Demetrio-Pablo: None declared, José Luis Martín-Varillas: None declared, Lara Sanchez-Bilbao: None declared, David Martínez-López: None declared, Iñigo González-Mazón: None declared, Miguel Á. González-Gay Speakers bureau: Abbvie, Pfizer, Roche, Sanofi and MSD., Grant/research support from: Abbvie, MSD, Janssen and Roche., Ricardo Blanco Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myer, Janssen, Lilly and MSD., Grant/research support from: Abbvie, MSD and Roche.
18
Ercalik, Tulay. "Efficacy of Intradiscal Ozone Therapy with or without Periforaminal Steroid Injection on Lumbar Disc Herniation: A Double-Blinded Controlled Study." Pain Physician 5;23, no. 9;5 (September 14, 2020): 477–84. http://dx.doi.org/10.36076/ppj.2020/23/477.
Повний текст джерелаАнотація:
Background: Intradiscal ozone therapy, a minimally invasive technique, is used in patients that do not respond to standard conservative therapies for low back pain due to degenerative disc-induced lumbar disc herniation (LDH). Many studies on clinical efficacy lack a standardized injection method and are limited by inadequate study design. Objective: This study aimed to determine the efficacy of periforaminal steroid injection together with intradiscal ozone therapy. Study Design: A prospective, double-blinded, randomized controlled trial. Setting: A tertiary care center. Methods: This study was conducted in 65 patients with low back and leg pain caused by LDH. Group 1 received intradiscal ozone therapy (n = 35) and Group 2 received intradiscal ozone therapy with periforaminal steroid injection (n = 30). Patients were evaluated for pain using the visual analogue scale (VAS), for disability using Oswestry Disability Index (ODI), and for quality of life using the short form 36 health survey administered pre-injection and at one and 6 months postinjection. All procedures were performed under sterile conditions using C-arm fluoroscopy. Results: Significant improvements were observed in pain, disability, and quality of life in both groups post-treatment compared to pre-injection. Mean pre-injection VAS was not significantly different between the groups (VAS: 7.8 ± 1.1 for Group 1, 7.8 ± 1.2 for Group 2). VAS values at 6 months for Group 1 and Group 2 were as follows: 3.6 ± 2.4, 4.1 ± 1.6, respectively) (P < 0.001). Mean pre-injection ODI was not significantly different between the groups (ODI: 20.9 ± 9.6 for Group 1, 25.2 ± 10.3 for Group 2). ODI values at 6 months for Group 1 and Group 2 were as follows: 12.8 ± 9.2, 14.3 ± 7.2, respectively) (P < 0.001). However, there were no significant differences between the groups. Similarly, there was no significant difference between the 2 groups on any of these parameters. Limitations: A limited number of patients and limited follow-up time. Conclusion: This study showed that intradiscal ozone injection alone was sufficient to treat low back and leg pain caused by LDH and that periforaminal steroid injection does not provide additional benefit, which is contrary to the literature. Key words: Low back pain, intradiscal ozone, steroid, lumbar disc herniation, lumbar disc degeneration
19
SMULDERS, FRANS J. M., GABRIELE WELLM, JOHANN HIESBERGER, IRENE ROHRBACHER, ALEXANDRA BAUER, and PETER PAULSEN. "Microbiological and Sensory Effects of the Combined Application of Hot–Cold Organic Acid Sprays and Steam Condensation at Subatmospheric Pressure for Decontamination of Inoculated Pig Tissue Surfaces." Journal of Food Protection 74, no. 8 (August 1, 2011): 1338–44. http://dx.doi.org/10.4315/0362-028x.jfp-10-472.
Повний текст джерелаАнотація:
We studied microbiological and sensory effects of treating pig tissue for 15 s with 55 and 10°C sprays of acetic acid (AA; 0.15 to 0.3 M) and lactic acid (LA; 0.1 to 0.2 M) solutions prior to the tissue being subjected to steam condensation (18 s at 65°C or 10 s at 75°C). LA or AA spraying and then steam treatment resulted in 3- to 4-log average reductions of Pseudomonas fragi and Yersinia enterocolitica inocula (6 to 7 log CFU/cm2), regardless of acid temperature or concentration. Buffered LA or 1:1 mixtures of AA:LA and then steam treatment yielded similar reductions. Most of the acid-steam–treated samples had microbial counts below the limit of detection (2 log CFU/cm2); thus, the results likely underestimate the potential of this procedure. When the period between inoculation and acid–steam treatment was extended from 0.5 to 24 h, up to a 1-log-higher microbial reduction was observed, due to a 1- to 2-log-greater initial contamination. Increasing the LA contact time to 6 min increased the microbial reduction by 0.8 log. Acid–steam treatment effected lower L* values (darker color) on pigskin, but higher L* values on muscle and fat tissue (paler color). Many muscle samples exhibited lower a* values and off-color brown hues. Off-odors were observed immediately after treatment, but with the exception of fat tissue and AA-treated samples, they largely disappeared during further storage. Off-flavors were only detected in AA-treated muscle samples.
20
Addasi, Alaa. "Hodgkin Lymphoma in Jordan; A Retrospective Analysis of 477 Cases in King Hussein Cancer Centre." Blood 118, no. 21 (November 18, 2011): 4862. http://dx.doi.org/10.1182/blood.v118.21.4862.4862.
Повний текст джерелаАнотація:
Abstract Abstract 4862 BACKGROUND Jordan is a small country with an estimated mid year population in 2008 of 5 850 000, 3015000 of whom are males and 2 835 000 are females (male: female ratio 1.06: 1). (Department of Statistics Jordan, 2008). About 12.7 % of the population is under 5 years old, and 37.3 % under 15 years old. 11%if the population are 15–19 year old, with a M:F ratio 1.06:1 as well) Only 3.3 % of the total population is above the age of 65 years old (sex ratio of 1.01 male per 1 female in this age group). According to the Jordan Cancer Registry Report for 2008, Lymphoma is the fourth most common Cancer in the country. A total of (4606 ) new cases of cancer were recorded among Jordanians in the year 2008, 333 (7.2%) of whom had a diagnosis of lymphoma.111 (2.4%) were diagnosed as Hodgkin's lymphoma (HL), and 222 (4.8%) as Non Hodgkin Lymphoma(NHL). OBJECTIVE In this study, we aim to characterize some of the clinico-pathological features of Hodgkin lymphoma in Jordan by analyzing the data available for patients referred to King Hussein Cancer Center over a seven year period. PATIENTS AND METHODS A retrospective analysis was conducted of adults (>18 years) lymphoma patients referred to KHCC, between 1/1/2003 and 31/12/2010. Clinical features and histological subtypes were prospectively established for all patients registered in the Lymphoma Service Database. Pathology review and original paraffin block were mandated for all patients. RESULTS Over the 8 year period of 2003–2010,1329 lymphoma patients were referred to KHCC and registered in the Lymphoma Service Database, of whom 477 (35.9%) were diagnosed with Hodgkin's lymphoma. Among this group all 477 patients were adults 18 years or older (100%), as children are treated in a different department. The median age was 35 years, (with an age range of 18–77), and 5% of patients were above the age of 60. 290 (61 %) of the patients were males, 187 (39%) were females, with a male to female (M:F) ratio of 1.55:1. 276 (57.8%) of the HL cases had a diagnosis of nodular sclerosis Hodgkin lymphoma (HDNS), making it the most common histological subtype. 120(25.2%) had mixed cellularity Hodgkin lymphoma (HDMC), 9 (1.9%) had lymphocyte-rich Hodgkin lymphoma (HDLR), and 6 (1.2%) had lymphocyte-depleted Hodgkin (HDLD). Nodular lymphocyte predominance Hodgkin lymphoma (NLPHD) cases were 33, and constituted 6.9% of the HL cohort. CONCLUSION Hodgkin lymphoma appears to constitute a bigger share of the lymphoma burden in Jordan, as opposed to Europe and the US. Clinico-pathological features, however, appear to be closer to those described in Western countries, with similar incidence of HDNS, and HDMC subtypes, but possibly with less incidence of HDLR and HDLD subtypes. Disclosures: No relevant conflicts of interest to declare.
21
Gold, Audra L., Erika Meza, Sarah F. Ackley, Dan M. Mungas, Rachel A. Whitmer, Elizabeth Rose Mayeda, Sunita Miles, Chloe W. Eng, Paola Gilsanz, and M. Maria Glymour. "Are adverse childhood experiences associated with late-life cognitive performance across racial/ethnic groups: results from the Kaiser Healthy Aging and Diverse Life Experiences study baseline." BMJ Open 11, no. 2 (February 2021): e042125. http://dx.doi.org/10.1136/bmjopen-2020-042125.
Повний текст джерелаАнотація:
ObjectivesEvidence on adverse childhood experiences (ACEs) and late-life cognitive outcomes is inconsistent, with little research among diverse racial/ethnic groups. We investigated whether ACE exposures were associated with worse late-life cognition for all racial/ethnic groups and at different ages of exposure.DesignCovariate-adjusted mixed-effects linear regression models estimated associations of: (1) total number of ACEs experienced, (2) earliest age when ACE occurred and (3) type of ACE with overall cognition.SettingKaiser Permanente Northern California members aged 65 years and older, living in Northern California.ParticipantsKaiser Healthy Aging and Diverse Life Experiences study baseline participants, aged 65 years and older (n=1661; including 403 Asian-American, 338 Latino, 427 Black and 493 white participants).ResultsMost respondents (69%) reported one or more ACE, most frequently family illness (36%), domestic violence (23%) and parental divorce (22%). ACE count was not adversely associated with cognition overall (β=0.01; 95% CI −0.01 to 0.03), in any racial/ethnic group or for any age category of exposure. Pooling across all race/ethnicities, parent’s remarriage (β=−0.11; 95% CI −0.20 to −0.03), mother’s death (β=−0.18; 95% CI −0.30 to −0.07) and father’s death (β=−0.11; 95% CI −0.20 to −0.01) were associated with worse cognition.ConclusionAdverse childhood exposures overall were not associated with worse cognition in older adults in a diverse sample, although three ACEs were associated with worse cognitive outcomes.
22
Álvarez-Reguera, C., J. J. Gaitán-Valdizán, R. Fernández-Ramón, R. Demetrio-Pablo, J. L. Martín-Varillas, L. Sanchez-Bilbao, D. Martínez-López, I. González-Mazón, M. Á. González-Gay, and R. Blanco. "OP0091 TREATMENT OF OCULAR SARCOIDOSIS. STUDY OF 65 PATIENTS OF A SERIES OF 384 PATIENTS FROM A SINGLE UNIVERSITY HOSPITAL." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 50.1–50. http://dx.doi.org/10.1136/annrheumdis-2021-eular.1896.
Повний текст джерелаАнотація:
Background:Ocular involvement is a relatively frequent and potentially severe complication of sarcoidosis. Oral corticosteroids (OCS) are the first-line treatment. Conventional immunosuppressive agents (cIS) and biological therapy (BT) can be used in refractory cases (1-5).Objectives:To evaluate the treatment and visual outcomes of a cohort of patients diagnosed with ocular sarcoidosis.Methods:Study of a large cohort (n=384) of all consecutive patients diagnosed with sarcoidosis from January 1, 1999 to December 31, 2019 at a single University Hospital. Finally, 344 patients were included according the ATS/ERS/WASOG criteria (Eur Respir J. 1999; 14:735-7). Different ocular manifestations and the following systemic treatments were assessed: a) OCS, b) cIS), c) monoclonal TNF inhibitors, d) Etanercept (ETN), e) Tocilizumab (TCZ). Best Corrected Visual Acuity (BCVA) according to different systemic treatments was compared at diagnosis and after one year of follow-up (Kruskall Wallis test).Results:344 patients were reviewed. From these, 65 (18.9%) presented ocular manifestations as uveitis (83.1%), orbital lesions (7.7%), retinal vasculitis (6.2%), dry eye (6.2%) and scleritis (1.5%). All of them received systemic treatment. BT was particularly used in patients with retinal vasculitis (100%), panuveitis (75%) and orbital lesions (40%). Systemic treatment and BCVA outcome according to ocular manifestations are shown in table. Median BCVA at onset and after one year was 0.6 [interquartile range (IQR) 0.3-0.8] and 0.9 [0.6-1], respectively. No statistically significant differences were observed between systemic treatments in BCVA of patients with uveitis after 1 year of follow-up (Figure).Figure 1.Median [25,75 IQR] BVCA after one year follow up according to type of systemic treatment in sarcoid uveitis.Median BCVA after one year Systemic treatmentAbbreviations: BCVA: Best Corrected Visual Acuity; OCS: Oral Corticosteroids; Conventional IS: Conventional immunosupressants; Monoclonal TNFi: monoclonal tumour necrosis factor inhibitors; ETN: Etanercept; TCZ: Tocilizumab.Conclusion:Panuveitis, intermediate uveitis and orbital lesions, require a more aggressive treatment than other manifestations of ocular sarcoidosis. In uveitis, an important improvement in BCVA after 1 year of follow-up was observed regardless of the type of treatment used.References:[1]Riancho-Zarrabeitia L, et al. Semin Arthritis Rheum 2015;45(3):361-8. PMID: 26092330[2]Riancho-Zarrabeitia L et al. Clin Exp Rheumatol 2014;32(2):275-84. PMID: 24321604[3]Vegas-Revenga N, et al. Am J Ophthalmol 2019; 200:85-94. PMID: 30660771[4]Cordero-Coma et al. Mediators Inflamm 2014; 2014:717598. PMID: 24976689[5]Calvo-Río V, et al. Clin Exp Rheumatol 2014; 32 (4 Suppl 84): S54-7. PMID: 25005576Table 1.Median BCVA at onset and after one year according to ocular manifestations and type of systemic therapy.Type of ocular affectationn (%)Median BCVA at onset [IQR]Median BCVA after 1 year [IQR]OCSn (%)cISn (%)monoclonal TNFin (%)ETNn (%)TCZn (%)Uveitis54 (83.1)0.6 [0.3-0.8]0.9 [0.6-1]44 (81.5)29 (53.7)16 (29.6)3 (5.5)3 (5.5) -Anterior31 (47.7)0.7 [0.3-0.8]0.8 [0.5-1]22 (70.9)12 (38.7)2 (6.5)2 (6.5)0 -Intermediate2 (3.1)0.50.72 (100)1 (50)1 (50)1 (50)1 (50) -Posterior5 (5.2)0.5 [0.1-0.9]0.9 [0.9-1]4 (80)4 (80)3 (60)00 -Panuveitis16 (24.6)0.4 [0.2-0.7]0.9 [0.5-1]16 (100)12 (75)10 (62.5)02 (12.5)Orbital lesions5 (7.7)0.5 [0.1-0.6]1 [0.1-1]4 (80)2 (40)2 (40)01 (20)Retinal vasculitis4 (6.2)0.6 [0.5-0.8]1 [0.6-1]4 (100)4 (100)1 (25)01 (25)Dry eye4 (6.2)10.92 (50)1 (25)000Scleritis1 (1.5)111 (100)0000Abbreviations: BCVA: Best Corrected Visual Acuity; IQR: Interquartile Range; OCS: Oral Corticosteroid; cIS: Conventional Immunosuppressants; Monoclonal TNFi: monoclonal tumour necrosis factor inhibitors; ETN: Etanercept; TCZ: Tocilizumab.Disclosure of Interests:Carmen Álvarez-Reguera: None declared, Jorge Javier Gaitán-Valdizán: None declared, Raúl Fernández-Ramón: None declared, Rosalía Demetrio-Pablo: None declared, José Luis Martín-Varillas: None declared, Lara Sanchez-Bilbao: None declared, David Martínez-López: None declared, Iñigo González-Mazón: None declared, Miguel Á. González-Gay Speakers bureau: Abbvie, Pfizer, Roche, Sanofi and MSD., Grant/research support from: Abbvie, MSD, Janssen and Roche., Ricardo Blanco Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen, Lilly and MSD., Grant/research support from: Abbvie, MSD and Roche.
23
Palumbo, Antonio, Meletios A. Dimopoulos, Katja Weisel, Michele Cavo, Enrique M. Ocio, Paolo Corradini, Michel Delforge, et al. "Outcomes for Older Patients in Stratus (MM-010), a Single-Arm, and Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma." Blood 124, no. 21 (December 6, 2014): 4770. http://dx.doi.org/10.1182/blood.v124.21.4770.4770.
Повний текст джерелаАнотація:
Abstract Background: Survival of patients (pts) with multiple myeloma (MM) decreases with increased age (Pulte, Oncologist, 2011). In addition, MM pts with advanced disease who have exhausted treatment (Tx) with novel agents have a poor prognosis (Kumar, Leukemia, 2012). Pomalidomide (POM) is a new oral agent with antimyeloma, stromal cell inhibitory, and immune modulatory effects (Quach, Leukemia, 2010; Mark, Leuk Res, 2014). In the pivotal MM-003 trial, POM in combination with low-dose dexamethasone (LoDEX) demonstrated significant progression-free survival (PFS) and overall survival (OS) benefits vs. high-dose dexamethasone, with a tolerable safety profile in refractory or relapsed and refractory MM (RRMM; Dimopoulos, Blood, 2013). In MM-003, significant PFS and OS benefits with POM + LoDEX Tx were seen in different age groups; tolerability and dose intensity were not affected by age (Weisel, Blood, 2013). STRATUS is a multicenter, single-arm, open-label, European, phase 3b trial to further evaluate safety and efficacy of POM + LoDEX in a large pt population. This analysis examines outcomes by age (≤ 65 vs. > 65 yrs, and ≤ 70 vs. > 70 yrs). Methods: Eligible pts had refractory or relapsed and refractory disease (progressive disease [PD] during or within 60 days of last line of Tx), having previous BORT and LEN failure and adequate prior alkylator therapy as defined in study protocol. Pts must have been refractory to the last prior Tx line. Pts with Eastern Cooperative Oncology Group performance status > 2 were excluded. Pts received 28-day cycles of POM 4 mg D1-21 + DEX 40 mg (20 mg for pts aged > 75 yrs) once weekly. All pts received thromboprophylaxis with low-dose aspirin, low-molecular-weight heparin, or equivalent based on clinical recommendations. Tx continued until PD or unacceptable toxicity. The primary endpoint was safety; the secondary endpoints included POM exposure, overall response rate (ORR; ≥ partial response), duration of response (DOR), PFS, and OS. Outcomes were analyzed by pt age at baseline (≤ 65 vs. > 65 yrs, and ≤ 70 vs. > 70 yrs). Results: As of March 17th, 2014, a total of 456 pts have been enrolled, and 452 had received POM + LoDEX; 48% were aged ≤ 65 yrs, 52% were > 65 yrs, 71% were ≤ 70 yrs, and 29% were > 70 yrs. Pts were heavily pretreated (median 4-5 prior Tx depending on age subgroup). Median follow-up was 6.8 mos. Younger pts (≤ 65 yrs) were more likely to have better renal function (creatinine clearance ≥ 60 mL/min; 80%) than those aged > 65 (49%). Median relative dose intensity was similar independent of age (range, 0.95-0.97 mg/day). The most common grade (Gr) 3-4 treatment-emergent adverse events (TEAEs) across age groups were neutropenia, anemia, thrombocytopenia, and pneumonia (Table). Gr 3-4 deep vein thrombosis (DVT) with prophylaxis was 1% in each subgroup. Discontinuations of POM due to TEAEs were low in pts aged ≤ 65 (0.9%), > 65 (3.0%), ≤ 70 (1.3%), and > 70 (3.8%) yrs. Outcomes by age are summarized in the Table. ORR was consistent for pts aged ≤ 65 (38%), > 65 (32%), ≤ 70 (35%), and > 70 (34%) yrs; DORs were 5.1, 6.8, and 5.8 mos and not estimable (NE) in these pt populations, respectively. Median PFS and median OS were similar across all age groups (PFS range, 4.0-4.9 mos, OS range, 10.6-11.5 mos). Conclusions: The data reported here further demonstrate the tolerability and efficacy of POM + LoDEX in pts with RRMM in the age subgroups analyzed (≤ 65 vs. > 65 yrs and ≤ 70 vs. > 70 yrs). Safety profiles were consistent, while dose intensity was similar across age groups. PFS, OS, and response rates were comparable with those previously reported in trials of POM + LoDEX in pts with RRMM and reinforce 4 mg POM as an appropriate starting dose irrespective of age. These data support POM + LoDEX as a standard Tx option for pts with refractory or RRMM regardless of age. Table 1. Age ≤ 65 yrs (n = 215) Age > 65 yrs (n = 237) Age ≤ 70 yrs (n = 319) Age > 70 yrs (n = 133) Grade 3-4 TEAEs, % Neutropenia Anemia Thrombocytopenia Pneumonia 38 30 22 13 41 24 16 10 38 29 21 11 44 23 15 11 Grade 3-4 EOI, % DVT/PE PN 1 <1 1 2 1 1 1 2 Efficacy (n = 218) (n = 238) (n = 322) (n = 134) ORR (≥ PR), % (95% CI) Median DOR (95% CI), mos Median PFS (95% CI), mos Median OS (95% CI), mos 38 (31-44) 5.1 (3.8-6.7) 4.1 (3.3-4.9) 10.9 (9.0-NE) 32 (26-38) 6.8 (4.7-11.5) 4.6 (3.6-5.6) 10.6 (9.3-NE) 35 (30-41) 5.8 (20.0-28.1) 4.0 (3.2-4.8) 10.9 (9.2-NE) 34 (26-42) NE (34.4-NE) 4.9 (3.7-6.7) 11.5 (8.5-NE) EOI: events of interest; NE: Not evaluable. Disclosures Palumbo: Array BioPharma: Honoraria; Onyx Pharmaceuticals: Consultancy, Honoraria; Millennium Pharmaceuticals, Inc.: Consultancy, Honoraria; Janssen-Cilag: Consultancy, Honoraria; Celgene: Consultancy, Honoraria; Genmab A/S: Consultancy, Honoraria; Bristol-Myers Squibb: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Sanofi: Honoraria. Dimopoulos:Celgene: Consultancy, Honoraria. Weisel:Janssen: Consultancy, Honoraria; Onyx: Consultancy, Honoraria; BMS: Consultancy; Noxxon: Consultancy; Celgene Corporation: Honoraria. Cavo:Celgene: Consultancy, Honoraria, Speakers Bureau. Ocio:Celgene Corporation: Honoraria, Research Funding. Corradini:Celgene Corporation: Speakers Bureau. Delforge:Celgene Corp: Honoraria; Janssen: Honoraria. Oriol:Celgene Corporation: Consultancy. Goldschmidt:Celgene: Consultancy, Research Funding, Speakers Bureau. Slaughter:Celgene: Employment. Simcock:Celgene Corporation: Employment. Herring:Celgene Corporation: Employment. Peluso:Celgene: Employment. Sternas:Celgene Corp: Employment, Equity Ownership. Zaki:Celgene Corp: Employment, Equity Ownership. Moreau:Celgene Corporation: Honoraria, Membership on an entity's Board of Directors or advisory committees.
24
Hasanah, Nur, Fadly Putajaya, Lela Kania, Nur Wulan Adi Ismaya, and Nanda Nurul Aini. "Gambaran Penyakit Jantung Berdasarkan Demografi Dan Penggunaan Obat." Jurnal Kesehatan 10, no. 1 (May 31, 2021): 100–110. http://dx.doi.org/10.37048/kesehatan.v10i1.311.
Повний текст джерелаАнотація:
Jantung merupakan salah satu organ yang penting dalam tubuh manusia.Dengan adanya kelainan fungsi organ jantung maka bisa menyebabkan penyakit jantung dan pembuluh darah, penyakit jantung dan pembuluh darah merupakan penyebab kematian nomor 1 secara global dan merupakan penyakit tidak menular. Faktor resiko terserang penyakit jantung dan pembuluh darah meningkat seiring dengan bertambahnya usia, pola hidup yang tidak sehat, perokok berat, stress dan riwayat penyakit dalam keluarga. Penelitian ini bertujuan untuk mengetahui sebaran pasien penderita penyakit jantung di Rumah Sakit X di kota Tangerang Selatan periode 2015 sampai 2019 berdasarkan usai, jenis kelamin dan obat yang sering diresepkan oleh dokter untuk pasien penderita penyakit jantung. Jenis penelitian yang dilakukan bersifat deskriptif, menggunakan sumber data sekunder di peroleh dari data rekam medis, dan lembar resep. Jumlah sample 477 pasien dari jumlah total populasi 10.623 pasien, hasil penelitian menunjukan jenis kelamin pada laki-laki (72%), usia terbanyak diatas 65 tahun atau manula (48%), obat yang sering diresepkan dokter adalah Clopidogrel dan Bisoprolol. Dari data tersebut dapat disimpulkan dengan pola hidup sehat bisa menjaga kesehatan tubuh terlebih jantung, dan memperpanjang usia produktif seseorang.
25
Mozayen, Mohammad, Anteneh Tesfaye, and Khalil Katato. "Lymphopenia as a prognostic factor in renal cell carcinoma." Journal of Clinical Oncology 30, no. 5_suppl (February 10, 2012): 470. http://dx.doi.org/10.1200/jco.2012.30.5_suppl.470.
Повний текст джерелаАнотація:
470 Background: Lymphopenia is known to be a negative prognostic marker for NHL and hematological malignancies, recent observational studies evaluated the presence of lymphopenia and its impact in solid tumor like colon, lung and pancreatic cancer. We aim to assess the effect of Lymphopenia at the renal cell carcinoma (RCC) survival. Methods: A retrospective review of 207 patients diagnosed with RCC between 1995 and 2008 in a community hospital setting was done. Patients with additional malignancies, lymphoma of the kidneys, with no follow up data or no preoperative complete blood count test were excluded. Demographics, preoperative complete blood count, pathology, disease stage, operative note, and subsequent follow up data were reviewed. Lymphopenia was defined as absolute lymphocytic count < 1200/µl. Last follow up date was used to calculate the 3 year overall survival. The primary outcome was 3 year overall survival. Results: A total of 207 patients were included in the study. Caucasians were 176(85.9%), African Americans were 13.7% and Asians were 1(0.5%). Males (M) were 127 (62.3%) and females (F) were 77(37.7%). The median age of the study population was 65 (22-91. Clear cell histology was seen in 79%. Stage I was seen in 53.9%, II in 23.5%, III in 13.7% and IV in 8.8% of the study population. Lymphopenia was seen in 81 (40%) patients (95 CI 34-48). Lymphopenia was seen in 31.8% of stage I; 50% of stage II, 41.4% of stage III, and 65% of stage IV patients (p=0.017). Lymphopenia was seen in 28.6% of African Americans and 42.7% of Caucasians (p=0.11). Lymphopenia was seen in 32.1% of females and 45.7% of males (p=0.03). The 3 year overall survival for the study population was 67.3% (95% CI: 60.4-73.7). The 3-year overall survival for patients with lymphopenia was 60.5%, compared to 73.6% in non-lymphopenic patients (p=0.04). Conclusions: Lymphopenia was seen to be higher among males and Caucasians, more frequently at advanced stage at diagnosis. Patients with lymphopenia were observed to have significantly worse survival when compared to patients with normal lymphocytic count in RCC. We conclude that lymphopenia is considered as a negative prognostic factor for RCC, and needed to be studied in the correlation of other known prognostic factors.
26
Spyropoulos, Alex, Mohamed Hussein, Jay Lin, and David Battleman. "Rates of Venous Thromboembolism in Commercially Insured US Surgical Patients." Blood 112, no. 11 (November 16, 2008): 526. http://dx.doi.org/10.1182/blood.v112.11.526.526.
Повний текст джерелаАнотація:
Abstract Introduction: Venous thromboembolism (VTE) constitutes a major healthcare burden in the United States (US), despite being effectively prevented by VTE prophylaxis. However, many patients at risk for VTE receive inadequate prophylaxis, and this has prompted the development of national performance measures to help improve prescribing practices. This study investigates the rates of post-operative VTE prevention in a real-world population of commercially-insured US surgical patients, and identifies VTE risk factors in this group. Methods: Discharges from the PharMetrics database (January 2001–December 2005) that had ICD-9 codes for orthopedic or abdominal surgery and were aged ≥18 years were included in the study. Patients aged ≥65 years and not in a Medicare Risk group and those without complete records or health plan coverage were excluded. The primary outcome measure for this study was the rate of (and time to) symptomatic VTE following surgery (as identified by ICD-9 codes), and the secondary outcome measure was the identification of independent VTE risk factors using logistic regression analysis to control for patient and hospital characteristics. Results: 172,320 discharges met the study criteria, of which 23.9% underwent orthopedic surgery and 76.1% underwent abdominal surgery. Primary outcome measures are shown in Table 1. In summary, orthopedic discharges had a higher incidence of clinically symptomatic VTE (4.7%) than abdominal discharges (3.1%). Both types of surgery had a similar distribution of VTE into deep-vein thrombosis (DVT, 72.5–75.0% of all VTE respectively), pulmonary embolism (PE, 22.5–25.0% of all VTE respectively), or both DVT and PE (2.5% of all VTE). The median time to a VTE event was shorter in orthopedic discharges (median 30 days) than their abdominal surgery counterparts (median 65 days). When considering all discharges in a logistic regression analysis, a prior history of VTE was found to be the strongest independent predictor of VTE (odds ratio [OR] 10.2; 95% confidence interval [CI] 9.2–11.4; p<0.001). Other significant variables associated with VTE outcomes included orthopedic surgery rather than abdominal surgery (OR 1.4; 95% CI 1.4–1.6), increasing age (per year) (OR 1.02; 95% CI 1.01–1.02), male gender (OR 1.18; 95% CI 1.09–1.28), increasing index hospitalization length of stay (per day) (OR 1.06; 95% CI 1.05–1.06), and pre-index Charlson comorbidity index (OR 1.12; 95% CI 1.09–1.14). Conclusions: Many patients undergoing orthopedic or abdominal surgery are at risk for VTE, with approximately 1 in 25 patients in this analysis experiencing a clinical VTE event. Improved implementation of national performance measures may help reduce the overall burden of VTE in the United States. Table 1 – VTE event rates Total (N=172,320) Orthopedic Surgery (N=41,139) Abdominal Surgery (N=131,181) Event, n (%) VTE 5956 (3.5) 1944 (4.7) 4012 (3.1) DVT 4367 (2.5) 1458 (3.5) 2909 (2.2) PE 1439 (0.8) 438 (1.1) 1001(0.8) DVT + PE 150 (0.1) 48 (0.1) 102 (0.1) Time to VTE Event: (days, median) VTE 51 30 65 DVT 70 34 83 PE 46 20 26 DVT+PE 31 17 27.5
27
Ahmed, Shahid, Guojian Wei, June Lim, Florence Pilar M. Plaza Arnold, Tahir Abbas, Nayyar Iqbal, Lynn Dwernychuck, et al. "Immune response and its correlation with the disease activity in patients with advanced colorectal cancer (aCRC): Results from a prospective observational study." Journal of Clinical Oncology 32, no. 3_suppl (January 20, 2014): 471. http://dx.doi.org/10.1200/jco.2014.32.3_suppl.471.
Повний текст джерелаАнотація:
471 Background: Currently limited biomarkers are available to monitor disease status in cancer patients. Although host factors are critical in regulating cancer, the role of immune responses in aCRC is less clear. A predominant T helper 1 (Th1) response may be more effective to contain cancer than one with a substantial Th2 component. The Th1/Th2 phenotype can be inferred from relative prevalence of IgG isotypes among anti-cancer antibodies and may provide an innovative way to assess disease activity. The study aims to develop an ELISA assay to monitor IgG1:IgG2 and its utility in predicting disease status in aCRC. Methods: A validated ELISA assay (Bertech Pharma) utilizing CRC cell lines was developed to measure IgG1 (Th2) and IgG2 (Th1) levels. A sample size of 44 (24 CRC and 20 healthy control [HC]) was estimated to achieve 80% power and α error of 0.05 assuming that the assay correctly detect CRC specific antibody in > 80% cases. The IgG1:IgG2 was compared between/within groups with HC and aCRC. Results: Samples were collected from 62/66 individuals recruited at 2:1 over 1 yr. 43 CRC patients had median age of 65 yrs (39-86) and M:F 2.3:1. 25 had >1 metastatic site, 31 underwent primary tumor resection and 37 received chemotherapy. Using standard criteria, 14/43 (33%) CRC patients had elevated 1gG1 titer compared with 2/19 (10%) HCs (p = 0.06). Mean IgG1 of CRC group was 0.18±0.05 compared with 0.15±0.01 in HC (p = 0.01). Conversely, mean IgG2 level of CRC group was 0.26±0.11 compared with 0.38±0.15 in HC (p = 0.003). Mean IgG2:IgG1 of CRC group was 1.5±0.35 compared with 2.5±0.97 in HC (p < 0.001). Among 43 CRC patients, 7/12 (58%) with disease progression (DP) had elevated IgG1 compared 7/31 (23%) with stable disease (p = 0.03). Strikingly, 9/12 (75%) patients who died had elevated IgG1 compared with 5/31 (16%) who were alive during the follow up, p = 0.001. Logistic regression revealed positive association among elevated IgG1 and DP, HR:4.8 (95% CI:1.2-19.9) and mortality, HR:15 (95% CI:3.1-78.8). Conclusions: Our results revealed that patients with aCRC have abnormal IgG1:IgG2 compared with HC and elevated IgG1 (a predominant Th2 response) levels in aCRC correlate with DP and mortality.
28
Arefieva, T. I., T. L. Krasnikova, A. V. Potekhina, N. U. Ruleva, P. I. Nikitin, T. I. Ksenevich, B. G. Gorshkov, et al. "Synthetic peptide fragment (65–76) of monocyte chemotactic protein-1 (MCP-1) inhibits MCP-1 binding to heparin and possesses anti-inflammatory activity in stable angina patients after coronary stenting." Inflammation Research 60, no. 10 (July 10, 2011): 955–64. http://dx.doi.org/10.1007/s00011-011-0356-z.
Повний текст джерела
29
Smyth, Elizabeth C., Yeon Jou Lee, Ghassan Abou-Alfa, Susan Seo, Ali Shamseddine, Eileen O’Reilly, Hassan Farran, et al. "Gastrointestinal Cancer Educatinal Case Series: A 65 year-old Female with Locally Advanced Gastric Cancer and a Supraclavicular Lymph Node." Journal of Gastrointestinal Cancer 43, no. 1 (March 18, 2011): 93–96. http://dx.doi.org/10.1007/s12029-011-9273-1.
Повний текст джерела
30
Yoh, Kyung Ah, Ho Sup Lee, Lee Chun Park, Eun Mi Lee, Dae Jin Park, and Yang Soo Kim. "Prognostic Significance of Elevated Serum Ferritin Before Chemotherapy in Patients with Non-Hodgkin's Lymphoma." Blood 120, no. 21 (November 16, 2012): 5099. http://dx.doi.org/10.1182/blood.v120.21.5099.5099.
Повний текст джерелаАнотація:
Abstract Abstract 5099 Background: Elevated ferritin level before stem cell transplantation was documented an adverse prognostic factor for patients undergoing hematopoietic stem cell transplantation for hematologic malignancies. Until now, there have been reported few studies which suggested high serum ferritin level were associated with worse outcomes for lymphoma. The purpose of this study was to find the significance of high levels of serum ferritin for predicting survival outcome in patients with non-Hodgkin's lymphoma (NHL). Methods: A total of 267 patients who newly diagnosed and received an chemotherapy at the Kosin University Gospel Hospital, Busan, South Korea between September 1999 and April 2012 were enrolled retrospectively in the current study. Pretreatment serum ferritin was measured within 2 weeks before the beginning of first line chemotherapy. The enrolled diseases included diffuse large B cell lymphoma (DLBL, n=163, 61. 0%), T cell lymphoma (TCL, n=48, 18. 0%) and other lymphoma (n=56, 21. 0%) including mantle cell lymphoma, marzinal zone B cell lymphoma, follicular lymphoma, small lymphocytic lymphoma and burkitt's lymphoma. In this study, patients with Hodgkin's disease and with undergoing chemotherapy 3 cycles or less than 3 cycles were excluded. Results: The median age of patients was 56 years (range, 14–84 years) and the mean level of serum ferritin at pre-treatment was 257. 79 ng/ml (range: 1. 70–6562. 00). In univariate anaylsis, factors associated with prolonged progression free survival (PFS) were LDH (p < 0. 001, 65. 8% in less than normal limit vs 39. 3% in more than normal limit), stage (p=0. 003, 64. 3% in less than stage III vs 46. 1% in stage III or more than), CRP (p = 0. 001, 58. 8% in less than 5mg/dL vs 27. 0% in 5mg/dL or more than), beta2-microglobulin (p < 0. 001, 59. 2% in less than 3. 5mg/L vs 29. 4% in 3. 5 mg/L or more than), and serum ferritin (p < 0. 001, 59. 2% in less than 500 ng/ml vs 22. 1% in 500 ng/ml or more than). Factors associated with prolonged overall survival (OS) were age (p < 0. 001, 61. 5% in less than 60 years vs 38. 4% in 60 years or more than), LDH (p < 0. 001, 70. 9% in less than normal limit vs 30. 0% in more than normal limit), ECOG performance status (p < 0. 001, 72. 8% in less than 2 scores vs 41. 9% in 2 scores or more than), stage(p=0. 005, 63. 4% in less than stage III vs 42. 1% in stage III or more than), Bulky mass (p = 0. 001, 57. 4% in tumor diameter less than 10cm vs 33. 5% in 10cm or more than), CRP (p = 0. 001, 60. 4% in less than 5mg/dL vs 27. 0% in 5mg/dL or more than), beta2-microglobulin (p < 0. 001, 59. 3% in less than 3. 5 mg/L vs 16. 3% in 3. 5 mg/L or more than), absolute lymphocyte count (p < 0. 001, 32. 2% in less than 1. 0 × 103/uL vs 59. 2% in 1. 0 × 103/uL or more than) and serum ferritin (p < 0. 001, 56. 9% in less than 500 ng/ml vs 23. 6% in 500 ng/ml or more than). In multivariate analysis, high level of LDH (RR (relative risk) = 0. 561, 95%CI: 0. 035–0. 890, P=0. 014), high level of beta2-microglobulin (RR= 0. 491, 95%CI: 0. 274–0. 880, P=0. 017) and high levels of serum ferritin (RR= 0. 557, 95%CI: 0. 311–0. 997, P=0. 049) were significant independent prognostic factors for PFS and high level of LDH (RR= 0. 418, 95%CI: 0. 269–0. 650, P < 0. 001), poor performance status (RR= 0. 467, 95%CI: 0. 295–0. 741, P=0. 001), high level of beta2-microglobulin (RR= 0. 461, 95%CI: 0. 278–0. 764, P=0. 003), and high levels of serum ferritin (RR= 0. 562, 95%CI: 0. 329–0. 958, P=0. 034) were significant independent prognostic factors for OS. Conclusions: High serum ferritin level of 500 ng/ml or more than 500 ng/ml may prognostic factor for survival outcomes including high LDH level, poor performance status, and high level of beta2-microglobulin in NHL. However, further studies are needed to confirm prognostic value of serum ferritn. Disclosures: No relevant conflicts of interest to declare.
31
Hakim, M. A., A. Hossain, Jaime A. Teixeira da Silva, V. P. Zvolinsky, and M. M. Khan. "Protein and Starch Content of 20 Wheat (Triticum aestivum L.) Genotypes Exposed to High Temperature Under Late Sowing Conditions." Journal of Scientific Research 4, no. 2 (April 28, 2012): 477. http://dx.doi.org/10.3329/jsr.v4i2.8679.
Повний текст джерелаАнотація:
A total of 20 spring wheat genotypes were evaluated under three growing conditions (optimum, late and very late) at the research farm of the Wheat Research Center, Bangladesh to assess the variation in grain yield, protein and starch content under heat stress. All genotypes were significantly affected by high temperature stress in late and very late sowing conditions, resulting in a decrease in days to heading and maturity, ultimately affecting yield, protein and starch content. Considering yield performance, genotype E-8 was best under optimum (6245 kg ha-1), late (5220 kg ha-1) and very late sowing (4657 kg ha-1) conditions while E-40 was the worst. With respect to yield reduction, genotype E-72 was heat-tolerant (13% yield reduction) while Prodip (49% yield reduction) was heat-susceptible. On the other hand, it was found that the percentage protein increased as heat stress increased. Under heat stress, genotype E-65 and E-60 had the highest and lowest protein content (15.5% and 12%), respectively. With respect to starch content, Prodip and E-37 had the highest while E-14 and E-72 had the lowest content (64.8% vs. 62.9%), respectively in all sowing conditions. Keywords: Yield; Protein; Starch; Wheat. © 2012 JSR Publications. ISSN: 2070-0237 (Print); 2070-0245 (Online). All rights reserved. doi: http://dx.doi.org/10.3329/jsr.v4i2.8679 J. Sci. Res. 4 (2), 477-489 (2012)
32
Fitriangga, Agus, Gerry Albilardo, and Muhammad Pramulya. "DISTRIBUTION AND SPATIAL PATTERN ANALYSIS ON MALNUTRITION CASES: A CASE STUDY IN PONTIANAK CITY." Malaysian Journal of Public Health Medicine 20, no. 2 (October 1, 2020): 56–64. http://dx.doi.org/10.37268/mjphm/vol.20/no.2/art.477.
Повний текст джерелаАнотація:
Based on the Basic Health Research (Riskesdas) in 2018, malnutrition cases in West Kalimantan reached 23.8 percent. In 2015, Pontianak City documented 27 cases of malnutrition. Then, the cases increased in 2016 and 2017 as many as 29 and 41 cases. The utilization of Geographic Information System (GIS) is required as a method for public health surveillance and monitoring. This study aims to analyze the distribution of malnutrition cases based on several clinical and non-clinical factors using GIS between 2016 to 2017. The dependent variable was malnutrition cases and the independent variables included household income level, parent’s educational level, comorbidities factors, and distance to the primary health care service. A total of 65 cases of malnutrition in Pontianak City were collected from six sub-districts in Pontianak City. This research was a cross-sectional study. The results showed that of 65 cases of malnutrition occurred on under 5-year-old children in Pontianak in 2016-2017, malnutrition cases taking place in East Pontianak sub-district were 29 cases (44.6%). In addition, malnutrition with clinical symptoms was reported 63 cases (96.9%), while the distance from home to primary health care less than 1 km was 32 cases (49.23%). The study also revealed that malnutrition with comorbidities were 78,5%. Finally, household income levels with malnutrition were below Pontianak regional minimum wage (Rp 2,515,000/month or $176,88). The mapping of malnutrition cases using Geographic Information Systems can facilitate the nutrition programmer in Pontianak City Health Office and Public Health Centre in intervening the social determinant of health to overcome malnutrition.
33
Motzek, Tom, Andreas Werblow, Jochen Schmitt, and Gesine Marquardt. "Administrative Prävalenz und Versorgungssituation der Demenz im Krankenhaus – Eine versorgungsepidemiologische Studie basierend auf GKV-Daten sächsischer Versicherter." Das Gesundheitswesen 81, no. 12 (February 5, 2018): 1022–28. http://dx.doi.org/10.1055/s-0043-125071.
Повний текст джерелаАнотація:
Zusammenfassung Ziel der Studie Menschen mit Demenz stellen das Versorgungsystem – und insbesondere die akutstationäre Versorgung – vor große Herausforderungen. Anhand von Routinedaten soll die kleinräumige administrative Prävalenz bzw. Diagnosehäufigkeit der Demenz, die administrative Prävalenz im Krankenhaus und die Versorgungssituation im Krankenhaus untersucht werden. Methoden Es wurden Routinedaten der gesetzlichen Krankenversicherung AOK PLUS für Sachsen im Jahr 2014 ausgewertet. Eine Demenz lag vor, wenn in mind. 3 von 4 Quartalen eine ambulante oder stationäre Demenzdiagnose identifiziert werden konnte (n=61 700). Für die Analysen der Versorgungssituation im Krankenhaus wurden 61 239 Personen mit und 183 477 Kontrollpersonen ohne Demenz eingeschlossen. Die Auswahl der Kontrollgruppe erfolgte gematched nach Alter, Geschlecht und Wohnort im Verhältnis 1:3. Ergebnisse Die administrative Ein-Jahres-Prävalenz bzw. Diagnosehäufigkeit der Demenz der über 65-Jährigen betrug 9,3%. Die Hochrechnung der administrativen Prävalenz der Demenz im Krankenhaus ergab für die über 65-jährigen Krankenhauspatienten eine Rate von 16,7%. Personen mit Demenz hatten um 33% mehr Krankenhauseinweisungen, eine um 36% längere Pro-Kopf Verweildauer und um 18% höhere akutstationäre Kosten je Personenjahr als Personen ohne Demenz. Die längere Verweildauer und höheren Kosten wurden überwiegend durch die höhere Einweisungshäufigkeit verursacht. Die akutstationären Inanspruchnahmen von Patienten mit Demenz waren – im Vergleich zu Patienten ohne Demenz – eher durch pflegerische und betreuende Bedarfe, als durch therapeutische und diagnostische Bedarfe charakterisiert. Schlussfolgerungen Um die Versorgungslage der Menschen mit Demenz zu verbessern, den Herausforderungen für die Krankenhäuser zu begegnen und um die finanziellen Belastungen der sozialen Sicherungssysteme zu reduzieren, sind zukünftig Verbesserungen notwendig. Dies umfasst unteren anderen Verbesserungen in den Erkennungsraten der Demenz und die Reduktion von vermeidbaren Krankenhauseinweisungen.
34
Pekov, Igor V., Natalia V. Zubkova, Atali A. Agakhanov, Vasiliy O. Yapaskurt, Nikita V. Chukanov, Dmitry I. Belakovskiy, Evgeny G. Sidorov, and Dmitry Yu Pushcharovsky. "New arsenate minerals from the Arsenatnaya fumarole, Tolbachik volcano, Kamchatka, Russia. VIII. Arsenowagnerite, Mg2(AsO4)F." Mineralogical Magazine 82, no. 4 (February 28, 2018): 877–88. http://dx.doi.org/10.1180/minmag.2017.081.067.
Повний текст джерелаАнотація:
ABSTRACTA new mineral arsenowagnerite, Mg2(AsO4)F, the arsenate analogue of wagnerite, was found in sublimates of the Arsenatnaya fumarole at the Second scoria cone of the Northern Breakthrough of the Great Tolbachik Fissure Eruption, Tolbachik volcano, Kamchatka, Russia. It is associated closely with johillerite, tilasite, anhydrite, hematite, fluorophlogopite, cassiterite, calciojohillerite, aphthitalite and fluoborite. Arsenowagnerite occurs as equant to tabular crystals up to 1 mm across combined in interrupted crusts up to 0.1 cm × 1.5 cm × 3 cm. The mineral is transparent, light yellow, lemon-yellow, greenish-yellow or colourless and has a vitreous lustre. Arsenowagnerite is brittle, with Mohs hardness of ~5. Cleavage is distinct, the fracture is uneven. Dcalc = 3.70 g cm–3. Arsenowagnerite is optically biaxial (+), α = 1.614(2), β = 1.615(2), γ = 1.640(2) and 2Vmeas = 25(5)°. Wavenumbers of the strongest absorption bands in the IR spectrum (cm–1) are: 874, 861, 507, 491 and 470. The chemical composition (average of six electron-microprobe analyses, wt.%) is: MgO 38.72, CaO 0.23, MnO 0.32, CuO 0.60, ZnO 0.05, Fe2O3 0.11, TiO2 0.03, SiO2 0.08, P2O5 0.18, V2O5 0.03, As2O5 54.96, SO3 0.10, F 8.91 and –O=F –3.75, total 100.57. The empirical formula calculated on the basis of 5 (O + F) apfu is: (Mg1.98Cu0.02Mn0.01Ca0.01)Σ2.02(As0.99P0.01)Σ1.00O4.03F0.97. Arsenowagnerite is monoclinic, P21/c, a = 9.8638(3), b = 12.9830(3), c = 12.3284(3) Å, β = 109.291(3)°, V = 1490.15(7) Å3 and Z = 16. The strongest reflections of the powder X-ray diffraction pattern [d,Å(I)(hkl)] are: 5.80(41)(002), 5.31(35)(120), 3.916(37)($\bar 2$21), 3.339(98)(221, 023), 3.155(65)(202), 3.043(100)($\bar 1$41), 2.940(72)($\bar 2$04), 2.879(34)($\bar 3$22) and 2.787(51)(320, $\bar 1$24). The crystal structure was solved from single-crystal X-ray diffraction data, R = 0.0485. Arsenowagnerite is isostructural to wagnerite-Ma2bc. The crystal structure is built by almost regular AsO4 tetrahedra, distorted MgO4F2 octahedra and distorted MgO4F trigonal bipyramids.
35
Humes, Larry E., and Dana L. Wilson. "An Examination of Changes in Hearing-Aid Performance and Benefit in the Elderly Over a 3-Year Period of Hearing-Aid Use." Journal of Speech, Language, and Hearing Research 46, no. 1 (February 2003): 137–45. http://dx.doi.org/10.1044/1092-4388(2003/011).
Повний текст джерелаАнотація:
This brief report describes the changes in hearing-aid performance and benefit in 9 elderly hearing-aid wearers over a 3-year period following the hearing-aid fitting. Objective measures of hearing-aid performance included three measures of speech recognition: (a) the Nonsense Syllable Test (NST) presented at 65 dB SPL and a +8 dB signal-to-noise ratio (SNR), (b) the Connected Speech Test (CST) presented at 50 dB SPL in quiet, and (c) the CST presented at 65 dB SPL and a +8 dB SNR. Subjective, self-report measures of hearing-aid benefit included the Hearing Aid Performance Inventory (HAPI; B. E. Walden, M. E. Demorest, & E. L. Helper, 1984) and the Hearing Handicap Inventory for the Elderly (HHIE; I. Ventry & B. Weinstein, 1982). Performance and benefit measures were obtained at postfit intervals of 1 month, 6 months, 1 year, 2 years, and 3 years using a standardized measurement protocol. Individual data were evaluated using 95% critical differences established previously for each benefit measure and applied around the scores observed at the 1-month postfit interval. Little evidence was seen for systematic improvement in aided performance or benefit, consistent with that expected from acclimatization, in any participant or for any measure of benefit.
36
Alpizar-Rodriguez, D., F. Irazoque-Palazuelos, T. S. Rodriguez-Reyne, E. Zamora, D. X. Xibille Friedmann, A. Castillo Ortiz, M. U. Martínez-Martínez, et al. "POS1242 FACTORS ASSOCIATED WITH MORTALITY IN PATIENTS WITH RHEUMATIC DISEASES AND COVID-19 IN MEXICO." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 904.1–904. http://dx.doi.org/10.1136/annrheumdis-2021-eular.3342.
Повний текст джерелаАнотація:
Background:As of the 25th of January 2021, more than 150 thousand deaths as consequence of COVID-19 have been reported in Mexico [1]. Advanced age, male gender and comorbidities have been described as risk factors for severe disease and mortality in general population [2]. COVID-19 mortality in Mexican patients with rheumatic and musculoskeletal diseases (RMDs) is unknown.Objectives:To describe characteristics of Mexican patients with RMDs and COVID-19, and to analyse factors associated with mortality.Methods:The Global Rheumatology Alliance COVID-19 (GRA) physician reported registry, is an international effort to collect information on COVID19 in adult patients with RMDs. GRA is an observational registry. The first patient from Mexico was registered on April 17, 2020. All Mexican patients registered in GRA until October 30, 2020 were included in this analysis. The association of mortality with demographic and clinical variables was estimated using logistic regression analysis.Results:A total of 323 patients were registered, with a median age of 52 (IQR 41-61) years old, 166 (51.4%) patients lived in Mexico City. The most frequent RMDs were rheumatoid arthritis, 149 (46.1%) and systemic lupus erythematosus, 24 (19.8%). Over a third of patients with RMDs and COVID-19 (119 (36.8%)) were hospitalized, and 43 (13.3%) died. Table 1 shows clinical and demographic characteristics. In the univariable analysis, the absence of comorbidities was a protective factor, OR 0.3 (95% CI 0.1-0.6). Factors associated with mortality at COVID-19 diagnosis were age over 65 years old, having type 2 diabetes, chronic renal insufficiency, treatment at COVID-19 diagnosis with corticosteroids or with CD20 inhibitors. In the multivariable adjusted analysis, these factors remained independently associated with mortality. No associations with other treatments or comorbidities at COVID-19 diagnosis were found.Conclusion:Mexican patients with RMDs and COVID-19 in the GRA physician reported registry had a mortality of 13.3%. Factors associated with mortality were those described in the general population, such as older age and being on corticosteroids and CD20 inhibitors treatment at COVID-19 diagnosis.References:[1]WHO. Coronavirus disease (COVID-19) pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. (accessed 26 January, 2021).[2]Zhou F, et al. Lancet 2020;395(10229):1054-62.Table 1.Clinical and demographic characteristics of patients with rheumatic diseases and COVID-19 in Mexico and mortality.Characteristics at COVID-19 diagnosisTotalN=323Death43 (13.3)Survivors280 (86.7)UnivariableOR (95% CI)MultivariableOR (95% CI)Women, n(%)268 (82.9)33 (76.7)235 (83.9)0.6 (0.3-1.4)0.5 (0.2-1.3)Age >65 years old, n(%)62 (19.2)18 (41.9)44 (15.7)3.9 (1.9-7.7)3.9 (1.9-8.3)RMDs* n(%)-Rheumatoid arthritis149 (46.1)23 (53.5)126 (45.0)1.6 (0.7-3.7)-Systemic Lupus Erythemathosus64 (19.8)10 (23.3)54 (19.3)1.6 (0.6-4.3)-Spondyloarthritis (axial and others)33 (10.2)2 (4.7)31 (11.1)0.1 (0.1-2.8)-Others77 (23.8)8 (18.6)69 (24.6)1-Moderate/High disease activity1, n(%)57 (18.6)7 (17.9)50 (18.7)1.0 (0.4-2.5)-None comorbidities, n(%)136 (42.1)8 (18.6)128 (45.7)0.3 (0.1-0.6)-Hypertension*, n(%)88 (27.2)12 (27.9)76 (27.1)1.0 (0.5-2.1)-Type 2 Diabetes*, n(%)49 (15.2)13 (30.2)36 (12.9)2.9 (1.4-6.1)2.4 (1.1-5.4)Obesity*, n(%)21 (6.5)3 (6.9)18 (6.4)1.1 (0.3-3.9)-Chronic obstructive pulmonary disease*, n(%)15 (4.6)1 (2.3)14 (5.0)0.5 (0.1-3.5)-Chronic renal insufficiency*, n(%)17 (5.2)6 (13.9)11 (3.9)3.9 (1.4-11.4)3.4 (1.1-10.4)Cardiovascular diseases*, n(%)14 (4.3)2 (4.7)12 (4.3)1.1 (0.2-5.0)-Corticosteroids*, n(%)171 (52.9)30 (69.7)141 (50.3)2.3 (1.1-4.5)3.0 (1.4-6.5)CsDMARD*, n(%)247 (76.5)33 (16.3)214 (76.4)1.0 (0.5- 2.2)-CD20 inhibitor*, n(%)21 (6.5)7 (16.3)14 (5.0)3.7 (1.4-9.9)4.9 (1.7-14.5)*Overlapped, 1 307 patients.Disclosure of Interests:None declared
37
Li, Kaizhi, Lei Li, Xiaoxiao Wu, Juan Yu, Hongjun Ma, Renya Zhang, Yan Li, and Wei Wang. "Loss of SDC1 Expression Is Associated with Poor Prognosis of Colorectal Cancer Patients in Northern China." Disease Markers 2019 (April 30, 2019): 1–7. http://dx.doi.org/10.1155/2019/3768708.
Повний текст джерелаАнотація:
Background. Syndecan-1 (SDC1/CD138) is a key cell surface adhesion molecule essential for maintaining cell morphology and the interactions with the surrounding microenvironment. SDC1 tumor immunoexpression may be increased or decreased in epithelial malignant neoplasms compared to that in adjacent non-neoplastic tissue, depending on the type of carcinoma, and it has been correlated with various clinicopathological parameters and patient prognosis. SDC1 expression is decreased in colorectal cancer (CRC) tissue, but the relationship between prognosis and SDC1 expression in CRC patients is controversial. Methods. In this study, SDC1 expression was detected in 65 adjacent non-neoplastic colorectal tissues, 477 CRCs, and 79 metastatic lymph nodes using tissue microarray. Results. The data show that SDC1 decreased in CRC tissues (p≤0.001) and metastatic lymph node tissues (p≤0.001) compared to that in adjacent non-neoplastic colorectal tissues. Loss of SDC1 protein expression is associated with poor overall (p<0.0001) and disease-free survival (p<0.0001), differentiation (p=0.017), stage (p≤0.001), and lymph node metastasis (p≤0.001) in CRC patients. Conclusions. These data suggest that the loss of SDC1 plays an important role in CRC malignant progression. Loss of SDC1 expression indicates poor prognosis in patients from northern China with CRC.
38
Dewhurst-Trigg, Rebecca, Alex J. Wadley, Rachel M. Woods, Lauren B. Sherar, Nicolette C. Bishop, Carl J. Hulston та Oonagh Markey. "Short-term High-fat Overfeeding Does Not Induce NF-κB Inflammatory Signaling in Subcutaneous White Adipose Tissue". Journal of Clinical Endocrinology & Metabolism 105, № 7 (31 березня 2020): 2162–76. http://dx.doi.org/10.1210/clinem/dgaa158.
Повний текст джерелаАнотація:
Abstract Context It is unclear how white adipose tissue (WAT) inflammatory signaling proteins respond during the early stages of overnutrition. Objective To investigate the effect of short-term, high-fat overfeeding on fasting abdominal subcutaneous WAT total content and phosphorylation of proteins involved in nuclear factor-κB (NF-κB) inflammatory signaling, systemic metabolic and inflammatory biomarkers. Design Individuals consumed a high-fat (65% total energy from total fat), high-energy (50% above estimated energy requirements) diet for 7 days. Results Fifteen participants (aged 27 ± 1 years; body mass index 24.4 ± 0.6 kg/m2) completed the study. Body mass increased following high-fat overfeeding (+1.2 ± 0.2 kg; P < 0.0001). However, total content and phosphorylation of proteins involved in NF-κB inflammatory signaling were unchanged following the intervention. Fasting serum glucose (+0.2 ± 0.0 mmol/L), total cholesterol (+0.4 ± 0.1 mmol/L), low-density lipoprotein cholesterol (+0.3 ± 0.1 mmol/L), high-density lipoprotein cholesterol (+0.2 ± 0.0 mmol/L), and lipopolysaccharide-binding protein (LBP; +4.7 ± 2.1 µg/mL) increased, whereas triacylglycerol concentrations (−0.2 ± 0.1 mmol/L) decreased following overfeeding (all P < 0.05). Systemic biomarkers (insulin, soluble cluster of differentiation 14 [CD14], C-reactive protein, interleukin-6, tumor necrosis factor-α and monocyte chemoattractant protein-1) and the proportion and concentration of circulating CD14+ monocytes were unaffected by overfeeding. Conclusion Acute lipid oversupply did not impact on total content or phosphorylation of proteins involved in WAT NF-κB inflammatory signaling, despite modest weight gain and metabolic alterations. Systemic LBP, which is implicated in the progression of low-grade inflammation during the development of obesity, increased in response to a 7-day high-fat overfeeding period.
39
Stadler, Michael, Elke Dammann, Stefanie Buchholz, Bernd Hertenstein, Juergen Krauter, Matthias Eder, and Arnold Ganser. "Long Term Results of Allogeneic Hematopoietic Cell Transplantation in Elderly Patients." Blood 114, no. 22 (November 20, 2009): 3388. http://dx.doi.org/10.1182/blood.v114.22.3388.3388.
Повний текст джерелаАнотація:
Abstract Abstract 3388 Poster Board III-276 BACKGROUND: Allogeneic hematopoietic cell transplantation (alloHCT) has curative potential in many hematologic malignancies; however, substantial treatment related toxicities have restricted its use to younger patients, mostly below 55 years of age. With the development of reduced intensity conditioning regimens, alloHSCT is being applied more widely in elderly patients, too. PATIENTS: Here we report long term results of all consecutive alloHCT recipients above the age of 55 years at our institution between October 1996 and April 2009. Among a total of 649 patients allotransplanted, 172 were more than 55 years old: 86 patients in the age group over 55 to 60 years, 61 patients in the cohort over 60 to 65 years, and 25 patients older than 65 years. RESULTS: 73 elderly patients were female and 99 male. Diagnoses included acute lymphoblastic leukemia (14 patients), acute myelogenous leukemia (AML, 57), myelodysplastic syndromes or secondary AML (71), chronic myelogenous leukemia (7), myelofibrosis (6), lymphoma (11), and multiple myeloma (6). Advanced disease was present in 131 patients (76%) at the time of transplant. 164 patients (95%) had a WHO performance score of 0 to 1. According to the HCT comorbidity index (HCTCI), 67 patients (39%) had no comorbid conditions, whereas 58 patients (34%) had 1 to 2, and 47 (27%) had 3 or more comorbidities (not significant). Conditioning regimens were of reduced intensity in 147 patients (85%, in the majority FLAMSA-based) and myeloablative in 25 patients (15%). 56 patients (33%) received a graft from a related donor and 116 (67%) from an unrelated donor. With a median follow-up of 11 months (range: less than 1 to 127), 55 patients have relapsed (32%). Non-relapse mortality was 27% (46 of 172 patients). At last follow-up, 80 of 172 patients (47%) were alive and 77 (45%) in complete remission. Probabilities of overall (OS) and disease-free survival (DFS) at four years were 40 and 35%, respectively. Interestingly, long term OS and DFS were similar among the patients aged 55 to 65 years when compared to the 477 patients below 55 years allotransplanted during the same period at our institution. Only the age cohort over 65 years had a significantly reduced outcome with 22% DFS at four years (p = 0.006). Comorbidities were distributed comparably in all three elderly age groups, but remained without statistical effect on survival, likely due to the overriding influence of high risk status. CONCLUSIONS: In our experience, alloHSCT was feasible in elderly patients of sufficient performance status, with acceptable toxicity and relapse rates, and with insignificant impact from comorbid conditions. Up to the age of 65 years, outcome was not inferior to that of patients below 55 years of age. Disclosures: No relevant conflicts of interest to declare.
40
Inamoto, Teruo, Hirotsugu Uemura, Norio Nonomura, Tatsuya Nakatani, Tadashi Matsuda, and Haruhito Azuma. "Efficacy and safety of sequential usage of everolimus in Asian patients with metastatic renal cell carcinoma (mRCC): Cooperative results from Osaka Urologic Oncology Group (OUOG)." Journal of Clinical Oncology 30, no. 5_suppl (February 10, 2012): 456. http://dx.doi.org/10.1200/jco.2012.30.5_suppl.456.
Повний текст джерелаАнотація:
456 Background: Data on the efficacy and safety of everolimus (EVE) in Japanese patients (pts) are lacking because only 15 Japanese pts enrolled in the EVE group from the RECORD-1 global study. Efficacy and safety of sequential usage of EVE after other targeted therapies or immunotherapy in Japanese pts were examined. Methods: We retrospectively reviewed the records of consecutive pts with mRCC (median age 65, M:F 78/22, 78% clear cell) who received salvage EVE at 39 tertiary institutions in Osaka Urologic Oncology Group (OUOG) between 10/09-8/11. Data on safety (NCI-CTC) and efficacy (response assessment, progression-free survival [PFS]) were analyzed. 31% of pts had progressed on sunitinib, 22% on sorafenib, 1% on axitinib, 41% on sequential (sunitinib:sorafenib), and 5% no prior therapy. 50% received previous cytokines in addition to targeted therapies. Results: 172 pts with mRCC were enrolled. Median PFS was 2.8 months. Median time to last follow-up was 3.5 months (range 0.4-15.2 months). 44% continued EVE at last follow-up. 4.7% had partial response (PR) and 51.7% had stable disease (SD) by treating physician assessment. Of 112 pts who discontinued EVE, 46% discontinued EVE due to progressive disease (PD) (median time to PD 3.0 months, range 0.1-15.8 months), 43% discontinued due to adverse events (AEs) (median time to PD 1.5 months, range 0.1-12.6 months), and 0.6% died of PD on treatment. There were no treatment related deaths. The incidence of AEs of all grades was 88.4%. Major AEs were stomatitis (44.2%), thrombocytopenia (30.8%), and interstitial lung diseases (ILD) (22.1%). The incidence of AEs (Grades 3-4) was 52.9%. Serious AEs were anemia (7.6%), ILD (5.8%), and hyperglycemia (4.7%). Time to onset for these AEs was less than one month, showing marked contrast to that of ILD which ranged over several months. Conclusions: EVE demonstrated clinically relevant activity in Japanese patients with mRCC following PD with other targeted therapies or immunotherapy. Patients prone to serious AEs should be carefully observed for the occurrence of ILD throughout the treatment period.
41
Selles, F., and R. P. Zentner. "Spring wheat yield trends in long-term fertility trials." Canadian Journal of Plant Science 73, no. 1 (January 1, 1993): 83–92. http://dx.doi.org/10.4141/cjps93-011.
Повний текст джерелаАнотація:
Results from a 16-yr fertility study conducted on fallow and stubble throughout southwestern Saskatchewan were used to assess the effects of technology adoption on spring wheat (Triticum aestivum L.) yields and the influence of available N on the yield effect of these new technologies. The magnitude of the residual trend (after the effect of growing-season precipitation was removed) was considered to reflect the yield increases attributable solely to the newly adopted technologies. Of the independent variables monitored, May and July precipitation and total available water on fallow plots were affected by time. Yields of wheat grown on stubble and fallow increased by an average 48 and 64 kg ha−1 yr−1, respectively. Of this annual yield increase, 52% on stubble and 78% on fallow were attributed to the adoption of new production technologies, with the remainder being explained by the trends observed in May and July precipitation. Nitrogen availability was an important factor in determining the magnitude of the trend due to technology adoption. The technology trend increased linearly from about 10 kg ha−1 yr−1, at the lowest available N levels, to about 65 kg ha−1 yr−1 when 98 kg N ha−1 was available; there were no further yield increases above this level of N. These results demonstrate that the full benefits of adopting new production technologies and more productive cultivars may not be achieved unless other growth-limiting factors, such as N availability, are removed. Further, this study demonstrates that researchers conducting long-term studies must be aware of possible time trends that may alter or obscure effects of treatments, thus making detrending procedures a basic requirement of data analyses in these types of studies. Key words: Spring wheat, yields, N fertilizer, available nitrogen, available water, trends
42
Davis, S. N., A. D. Cherrington, R. E. Goldstein, J. Jacobs, and L. Price. "Effects of insulin on the counterregulatory response to equivalent hypoglycemia in normal females." American Journal of Physiology-Endocrinology and Metabolism 265, no. 5 (November 1, 1993): E680—E689. http://dx.doi.org/10.1152/ajpendo.1993.265.5.e680.
Повний текст джерелаАнотація:
The aim of this study was to determine if insulin could augment the counterregulatory response to equivalent hypoglycemia in normal females similarly to males. Experiments were carried out in nine normal lean overnight-fasted female subjects. Insulin was infused in two separate randomized protocols so that steady-state levels of 794 +/- 62 (low) and 3,620 +/- 476 pM (high) were obtained. Despite an identical plasma glucose level (2.8 +/- 0.1 mM), epinephrine (5.7 +/- 0.9 vs. 3.9 +/- 0.6 nM), norepinephrine (2.7 +/- 0.4 vs. 1.8 +/- 0.3 nM), cortisol (918 +/- 55 vs. 826 nM), and growth hormone (35.8 +/- 3.7 vs. 28.4 +/- 2.7 micrograms/l) were increased (P < 0.05) during high compared with low insulin infusion, respectively. Glucagon and pancreatic polypeptide levels increased significantly but were not different during the two insulin infusions. Hepatic glucose production was increased during the high-compared with low-dose infusions (9.5 +/- 1.1 vs. 5.1 +/- 2.2 mumol.kg-1 x min-1; P < 0.05). Lipolysis, as indicated by the blood glycerol level, increased significantly during high- compared with low-dose insulin infusions (121 +/- 29 vs. 65 +/- 13 microM; P < 0.05). The hormonal and metabolic responses to hypoglycemia were significantly different in females compared with previous results in males.(ABSTRACT TRUNCATED AT 250 WORDS)
43
Choueiri, Toni K., Noah M. Hahn, Lillian Werner, Meredith M. Regan, and Jonathan E. Rosenberg. "Borealis-2: A randomized phase II study of OGX-427 (apatorsen) plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial cancer (mUC) (Hoosier Cancer Research Network GU12-160)." Journal of Clinical Oncology 35, no. 6_suppl (February 20, 2017): 289. http://dx.doi.org/10.1200/jco.2017.35.6_suppl.289.
Повний текст джерелаАнотація:
289 Background: OGX-427 (apatorsen; A) is an antisense oligonucleotide that binds Heat shock protein 27 (Hsp27) mRNA with synergistic effect with chemotherapy. Borealis-2 is a randomized multicenter phase 2 study of A in combination with docetaxel (D) vs. D alone in advanced UC patients (pts) after at least 1 prior platinum-based therapy. Methods: The primary objective was to determine whether D+A prolonged overall survival (OS) vs D. Patients were stratified (time from prior systemic chemotherapy; Bellmunt criteria) and randomized in a 1:1 ratio. D was administered for up to 10 cycles in both arms. OGX-427 maintenance continued in pts with no disease progression. Secondary objectives included safety, objective response, and serum levels of Hsp27. The trial design provided 90% power to detect a 33% decrease in OS hazard (hazard ratio [HR] = 0.667), with one-sided α = 0.10 after 162 deaths, and one interim futility analysis; a p-value < 0.1 would result in a positive study for the primary endpoint. Results: 200 pts were randomized between 8/2013 and 9/2015. 72.5% had 1-3 Bellmunt risk factors and 43.5% were < 3mos from prior chemotherapy. 163 pts had died (77 A+D; 86 D) at final analysis. The A+D group had a statistically-significant reduction in hazard for death vs. D (HR = 0.80; 80% CI, 0.65 to 0.98; one-sided P = 0.08). For A+D, median OS was 6.4 mos (95%CI 4.6-9.2) and 12-mo OS was 34.4% (95% CI 25.1-43.9). For D, median OS was 5.9 mos (95%CI 4.8-7.3) and 12-mo OS was 25.0% (95%CI 17.0-33.8). All causality grade 3 or higher toxicities were similar between A+D group (82%; 95%CI 73%-89%) and the D group (75%; 95%CI 65%-83%). The treatment effect of pts with baseline serum Hsp27 < 5.7ng/mL (median) vs. Hsp27 ≥ 5.7ng/mL was not different (2-sided p = 0.87 for interaction). Conclusions: In this platinum-pretreated population of advanced UC, adding OGX-427 to D provided a statistically significant improvement in OS and is worthy of further investigation in previously treated metastatic UC pts. Clinical trial information: NCT01780545.
44
Schweitzer, Daniel, Patricio Melero, Alejandro Zylberberg, Julian Salabarrieta, and Julio Urrutia. "Factors associated with avascular necrosis of the femoral head and nonunion in patients younger than 65 years with displaced femoral neck fractures treated with reduction and internal fixation." European Journal of Orthopaedic Surgery & Traumatology 23, no. 1 (January 6, 2012): 61–65. http://dx.doi.org/10.1007/s00590-011-0936-1.
Повний текст джерела
45
Schwartz, Kevin, Camille Achonu, Kevin Brown, Gary Garber, Jennie Johnstone, Bradley Langford, Valerie Leung, and Nick Daneman. "The Ontario Program To Improve AntiMIcrobial USE (OPTIMISE): A Descriptive Analysis of Dispensed Antibiotics." Open Forum Infectious Diseases 4, suppl_1 (2017): S20—S21. http://dx.doi.org/10.1093/ofid/ofx162.052.
Повний текст джерелаАнотація:
Abstract Background Antimicrobial resistant infections are an emerging global public health crisis. Antibiotic use is the largest modifiable risk factor for antimicrobial resistance. Greater than 90% of antibiotic use in Canada occurs outside of the hospital setting; however, there is a lack of data describing the patterns of community antibiotic use. Our objective was to describe outpatient antibiotic prescriptions for all of Ontario, Canada and to examine variability in antibiotic prescribing across physicians. Methods We conducted a cross-sectional study of antibiotics dispensed from community pharmacies in Ontario, Canada, between March 1, 2016 and February 28, 2017. Ontario has a population of 13.9 million people and over 30,000 physicians. We analyzed data from the Xponent™ database by QuintilesIMS. Xponent™ is based on data from 79% of retail pharmacies in Ontario. QuintilesIMS uses a geospatial extrapolation algorithm to project antibiotic utilization on 100% of the population. This analysis describes physician antibiotic prescribing patterns stratified by patient age and sex. Results There were 6,995,416 antibiotics dispensed or 501/1,000 population. The highest prescribing rate was for patients aged 65 and older at 702 antibiotic scripts/1,000 population, children 0–17 years received 477 antibiotic scripts/1,000 population and adults 18–64 years 446 antibiotics/1,000 population. Females aged 65 years and older received the highest number of antibiotics. Narrow spectrum penicillins, macrolides, first-generation cephalosporins, and second-generation fluoroquinolones (ciprofloxacin and norfloxacin) were the most common classes of antibiotics overall; however, the urinary antibiotics including ciprofloxacin, norfloxacin, and nitrofurantoin were the most common in older females (Figure 1). There was significant prescriber variability with 25% of all antibiotics being prescribed by 2.2% of physicians. Family physicians comprised 91% of these high prescribers. Conclusion This population-based study quantified community antibiotic utilization and demonstrated marked prescriber variability. Future antibiotic stewardship interventions should target the minority of family physicians that prescribe the majority of antibiotics. Disclosures All authors: No reported disclosures.
46
Dewi, Rismala, and Fatimatuzzuhroh Fatimatuzzuhroh. "Profil Pasien Sakit Kritis yang Dirawat di Pediatric Intensive Care Unit Rumah Sakit Cipto Mangunkusumo berdasar Sistem Skoring Pediatric Logistic Organ Dysfunction-2." Sari Pediatri 21, no. 1 (August 5, 2019): 37. http://dx.doi.org/10.14238/sp21.1.2019.37-43.
Повний текст джерелаАнотація:
Latar belakang. Skor PELOD-2 digunakan untuk mengetahui disfungsi organ pada anak dengan sakit kritis. Hasil skor PELOD-2 tidak selalu berbanding lurus dengan luaran perawatan anak sakit kritis sehingga tidak selalu dapat digunakan sebagai prediktor luaran dan mortalitas anak yang dirawat di PICU.Tujuan. Mengetahui profil dan luaran pasien sakit kritis yang dirawat berdasar skor PELOD-2.Metode. Penelitian dilakukan secara retrospektif dengan mengambil data rekam medis pasien rawat di ruang intensif anak RSUPN Cipto Mangukusumo, sejak Januari sampai Desember 2018. Pengambilan subjek secara total sampling, penilaian dilakukan pada 24 jam pertama perawatan. Hasil. Diperoleh 477 subjek yang memenuhi kriteria. Subjek sebagian besar berjenis kelamin laki-laki (56,4%), berusia <1 tahun (27,9%), dengan bedah sebagai diagnosis awal terbanyak (65%). Sebagian besar pasien memiliki penyakit kronik (70,4%). Angka mortalitas penelitian ini adalah 10,7%. Mayoritas subjek memiliki lama rawat <7 hari (75,5%). Subjek dengan lama rawat >14 hari memiliki median skor PELOD-2 tiga kali lipat dari subjek dengan lama rawat <7 hari. Titik potong luaran mortalitas skor PELOD-2 pada penelitian ini adalah >5, memiliki spesifisitas 84,5% dan sensitifitas 84,3% dengan nilai AUC skor PELOD-2 dari kurva ROC sebesar 93,4% (IK 95% 90,6–96,2).Kesimpulan. Skor PELOD-2 dapat digunakan untuk memprediksi disfungsi organ yang mengancam kehidupan pada anak tanpa imunosupresi dan semakin tinggi skor PELOD-2 akan diikuti dengan peningkatan lama rawat dan mortalitas.
47
Oki, Kentaro, Edward B. Arias, Makoto Kanzaki, and Gregory D. Cartee. "Effects of Acute Exercise Combined With Calorie Restriction Initiated Late-in-Life on Insulin Signaling, Lipids, and Glucose Uptake in Skeletal Muscle From Old Rats." Journals of Gerontology: Series A 75, no. 2 (October 1, 2018): 207–17. http://dx.doi.org/10.1093/gerona/gly222.
Повний текст джерелаАнотація:
Abstract We evaluated effects of calorie restriction (CR: consuming 60–65% of ad libitum [AL] intake) initiated late-in-life with or without acute exercise on insulin-stimulated glucose uptake (ISGU) of skeletal muscle by studying four groups of 26-month-old rats: sedentary-AL, sedentary-CR (8-week duration), 3 hours post-exercise (3hPEX)-AL and 3hPEX-CR. ISGU was determined in isolated epitrochlearis muscles incubated ± insulin. Muscles were assessed for signaling proteins (immunoblotting) and lipids (mass spectrometry). ISGU from sedentary-CR and 3hPEX-AL exceeded sedentary-AL; 3hPEX-CR exceeded all other groups. Akt (Ser473, Thr308) and Akt substrate of 160 kDa (AS160; Ser588, Thr642, Ser704) phosphorylation levels tracked with ISGU. Among the 477 lipids detected, 114 were altered by CR (including reductions in 15 of 25 acylcarnitines), and 27 were altered by exercise (including reductions in 18 of 22 lysophosphatidylcholines) with only six lipids overlapping between CR and exercise. ISGU significantly correlated with 23 lipids, including: acylcarnitine 20:1 (r = .683), lysophosphatidylethanolamine19:0 (r = −.662), acylcarnitine 24:0 (r = .611), and plasmenyl-phosphatidylethanolamine 37:5 (r = −.603). Muscle levels of ceramides (a lipid class previously linked to insulin resistance) were not altered by CR and/or exercise nor significantly correlated with ISGU, implicating other mechanisms (which potentially involve other lipids identified in this study) for greater ISGU and Akt and AS160 phosphorylation with these interventions.
48
Šudyová, Valéria, and Svetlana Šliková. "Contamination of Wheat Grains with Species of Genera Fusarium in Different Localities of Slovakia in 2006-2008." Agriculture (Polnohospodárstvo) 57, no. 3 (October 1, 2011): 110–17. http://dx.doi.org/10.2478/v10207-011-0012-1.
Повний текст джерелаАнотація:
Contamination of Wheat Grains with Species of GeneraFusariumin Different Localities of Slovakia in 2006-2008The frequency and relative density of occurrence ofFusariumspp. was evaluated on 112 wheat grain samples from different agro-ecological localities in Slovakia. The samples were collected in 2006, 2007 and 2008 from the same farmers and from the same localities every year immediately after harvest. In 2006, contamination was 95.2%, in 2007 it was 64.3%, and 71.4% in 2008. The highest average frequency of occurrence was found inFusarium graminearumin 2006 - 65%. The prevalence ofFusarium poaewas ascertained in 2007 and 2008. The highest frequency ofFusariumspp. occurrence was revealed in locality Turčiansky Ďur in 2008 - 53.9%. The highest identified amount ofFusariumspecies (12) was from the area of Turčiansky Ďur in 2007.Fusarium graminearum, Fusarium sporotrichioides, Fusarium poaeandFusarium oxysporumwere the most frequent in 2006, whileFusarium poae, Fusarium sporotrichioides, Fusarium graminearumandFusarium semitectumdominated in 2007.Fusarium poaedominated in 2008, then followedFusarium sporotrichioides, Fusarium graminearum, Fusarium oxysporumandFusarium avenaceum. Other identified species, such asFusarium equiseti, Fusarium tricinctumandMicrodochium nivale, were in population structure in a relatively low density. Grains contaminated withFusariumspp. are unsuitable for both human and animal consumption because of the adverse health effects of fusariotoxins.
49
Grano-Maldonado, M., A. Roque, H. Aguirre, and E. Fajer-Avila. "Egg morphology, larval development and description of the oncomiracidium of Heterobothrium ecuadori (Monogenea: Diclidophoridae) parasitising the bullseye pufferfish, Sphoeroides annulatus." Helminthologia 48, no. 1 (March 1, 2011): 51–55. http://dx.doi.org/10.2478/s11687-011-0009-3.
Повний текст джерелаАнотація:
AbstractThe present study is the first description of the egg morphology, embryonic development, and time required for hatching, and longevity of the oncomiracidium of Heterobothrium ecuadori (Meserve, 1938) Sproston, 1946. Experiments found that hatching time fluctuated between 7 and 10 days with a mean of 7.5 ± 1 days at 23 ± 1° C and 35 ‰. Eggs were provided with a polar filamentous appendage. The body of the oncomiracidium was flattened dorso-ventrally, 156 ± 9 μm long and 65 ± 8 μm wide. A full description of the egg development and morphology of the oncomiracidium is provided. The longevity of the oncomiracidia was 4–7 days at 21 ± 1°C, with a mean survival time of 121.8h. The ability to rear diclidophorids like H. ecuadori and to record precise information on their development provides valuable data for further studies.
50
Blais, Charles, Guy Drapeau, Philippe Raymond, Daniel Lamontagne, Nicole Gervais, Ingrid Venneman, and Albert Adam. "Contribution of angiotensin-converting enzyme to the cardiac metabolism of bradykinin: an interspecies study." American Journal of Physiology-Heart and Circulatory Physiology 273, no. 5 (November 1, 1997): H2263—H2271. http://dx.doi.org/10.1152/ajpheart.1997.273.5.h2263.
Повний текст джерелаАнотація:
The role of angiotensin-converting enzyme (ACE) in the metabolism of bradykinin (BK) has been studied in several tissues. However, and contrary to angiotensin I, the metabolism of BK at the cardiac level has not been investigated. In this study, we define the participation of ACE in the carboxy-terminal degradation of BK in heart membranes of the dog, human, rabbit, and rat. The calculation of the kinetic parameters characterizing the metabolism of BK and the generated des-Arg9-BK can be summarized as follows: the half-life ( t 1/2) of BK [dog (218 ± 32 s) > human (143 ± 9 s) = rat (150 ± 4 s) > rabbit (22 ± 2 s)] and of des-Arg9-BK [dog (1,042 ± 40 s) > human (891 ± 87 s) > rat (621 ± 65 s) > rabbit (89 ± 8 s)] both showed significant differences according to species. Enalaprilat, an ACE inhibitor, significantly prevented the rapid degradation of BK and des-Arg9-BK in all species studied, whereas retrothiorphan, a neutral endopeptidase inhibitor, and losartan, an angiotensin II type I receptor antagonist, did not affect this metabolism. The relative importance of ACE in the cardiac metabolism of BK was species related: dog (68.4 ± 3.2%) = human (72.2 ± 2.0%) > rabbit (47.7 ± 5.0%) = rat (45.3 ± 3.9%). ACE participation in the metabolism of des-Arg9-BK was as follows: rabbit (57.0 ± 4.0%) > dog (39.9 ± 8.8%) = human (25.4 ± 5.5%) = rat (36.0 ± 7.0%). The participation of cardiac kininase I (carboxypeptidase M) in the transformation of BK into des-Arg9-BK was minor: human (2.6 ± 0.1%) > dog (0.9 ± 0.1%) = rabbit (1.0 ± 0.1%) = rat (1.0 ± 0.1%). These results demonstrate that ACE is the major BK-degrading enzyme in cardiac membranes. However, the metabolism of exogenous BK by heart membranes is species dependent. Our observations could explain some discrepancies regarding the contribution of kinins in the cardioprotective effects of ACE inhibitors.